Review

Developmental Cues and Molecular Drivers in Myelinogenesis: Revisiting Early Life to Re-Evaluate the Integrity of CNS Myelin

Iasonas Dermitzakis 1, Maria Eleni Manthou 1, Soultana Meditskou 1, Dimosthenis Miliaras 1, Evangelia Kesidou 2, Marina Boziki 2, Steven Petratos 3, Nikolaos Grigoriadis 2 and Paschalis Theotokis 1,2, *

1 Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; iasonasd@auth.gr (I.D.); mmanthou@auth.gr (M.E.M.); sethym@auth.gr (S.M.); miliaras@auth.gr (D.M.)
2 Laboratory of Experimental Neurology and Neuroimmunology, Second Department of Neurology, AHEPA University Hospital, 54621 Thessaloniki, Greece; bioevangelia@yahoo.gr (E.K.); bozikim@auth.gr (M.B.); nigrigoriadis@auth.gr (N.G.)
3 Department of Neuroscience, Central Clinical School, Monash University, Prahran, VIC 3004, Australia; steven.petratos@monash.edu
* Correspondence: ptheotokis@auth.gr

Abstract: The mammalian central nervous system (CNS) coordinates its communication through saltatory conduction, facilitated by myelin-forming oligodendrocytes (OLs). Despite the fact that neurogenesis from stem cell niches has caught the majority of attention in recent years, oligodendrogenesis and, more specifically, the molecular underpinnings behind OL-dependent myelinogenesis, remain largely unknown. In this comprehensive review, we determine the developmental cues and molecular drivers which regulate normal myelination both at the prenatal and postnatal periods. We have indexed the individual stages of myelinogenesis sequentially; from the initiation of oligodendrocyte precursor cells, including migration and proliferation, to first contact with the axon that enlists positive and negative regulators for myelination, until the ultimate maintenance of the axon ensheathment and myelin growth. Here, we highlight multiple developmental pathways that are key to successful myelin formation and define the molecular pathways that can potentially be targets for pharmacological interventions in a variety of neurological disorders that exhibit demyelination.

Keywords: oligodendrogenesis; myelinogenesis; myelin formation; embryology; CNS development; neural tube development; morphogen signaling

1. Introduction

As the regulator of all cognitive, sensory, and motor activity, the nervous system is the most complex biological system in humans; the complexities of integrated neural networks are a hot area of intensive research that will require multidisciplinary investigations to address a variable array of neurological disorders that remain an unmet medical need. The main types of cells in the nervous system are neurons and glial cells with the latter performing vital supporting roles [1,2]. The glial/neuronal ratio differs uniformly across brain regions of mammalian species, underlining the pivotal role of interaction between glial cells and neurons for appropriate integration of the central nervous system (CNS) to coordinate neurophysiological and cognitive functions [3]. For propagation of action potentials to ensue in neurons, axonal myelination is crucial [4,5]. The cells responsible for myelination are the oligodendrocytes (OLs) in the CNS and Schwann cells in the peripheral nervous system (PNS). Rudolf Virchow initially designated the term "myelin" in 1854, named after the Greek word “marrow” (myelos), since it is especially plentiful in the brain’s center, or marrow [6]. He posited that neurons produced myelin, but Pió del Río Hortega’s
better histological staining processes almost a century ago revealed that myelin is created by specific glial cells, which are OLs [7,8].

The CNS macroglia and neurons have a common embryonic origin from the neuroectoderm, most prominently from neuroepithelial cells of the telencephalic ventricular and subventricular zone (VZ and SVZ), while the spinal cord is supplied with cell derivatives exclusively from the central canal [9,10]. Newborn CNS is radically unmyelinated with a sparse developing pool of unipotent cells, namely oligodendrocyte precursor cells (OPCs), following their birth with gradual widespread functionality in the first few years of childhood [11]. Myelination persists in an asynchronous spatiotemporal pattern through adolescence towards adulthood, coinciding with the establishment and maintenance of correct circuit function and cognitive development [12,13]. Mature myelin sheaths remain stable by and large; however, they maintain the capacity to remodel and reorganize if need be [14]. As expected, aging promulgates limit resources and energy deficiency to sustain such developmental processes, thus cellular senescence is a common event [15]. Consequently, there is a variety in the patterns of myelination, with qualitative- and quantitative-ontogenic checkpoints, throughout human life.

In this review, we focus on the de novo synthesis of myelin referred to herein as myelogenesis. This is the primordial pattern of myelination, which starts prenatally and predominates during the first two years of human life [16]. In order for myelogenesis to happen, neural stem cells (NSCs) need to undergo specific developmental stages, with the process of oligodendrogenesis, as well as additional steps for the maintenance of these primary myelin sheaths. Interestingly, it is possible that lifelong myelogenesis may still occur in specific CNS regions through quiescent, adult OPCs (aOPCs), based on miscellaneous factors, such as unmyelinated space, new OLs turnover, energy balance, and neural circuit activity [17]. Such processes are broadly defined as adaptive myelination or myelin remodelling/plasticity which is under fine regulation and is generally restricted. Lastly, another crucial factor that may trigger myelogenesis is injury and disease, such as demyelination, and is discussed briefly towards the end, with a process known as remyelination.

2. Myelogenesis and Myelin Development: A Spatiotemporal Coordination

2.1. Primordium Regions of OPCs

The mammalian CNS emerges from an ectodermal, neuroepithelial lining of the neural tube in the developing embryo [9,18]. Multiple divisions give rise to radial glia (RG), a multipotent neural stem population that colonizes the newly-formed ventricular walls (Figure 1) [18,19]. The VZ is the primary embryonic site for OPCs production through asymmetrical division of the RG cells. In mice, OPCs are firstly detected in the ventral VZ closer to the floor plate on embryonic day 12.5 (E12.5), and in humans at gestational week (GW) 6.5 (~E45) [20]. More specifically, the outer SVZ (oSVZ) is an enlarged cortical germinal zone only generated in humans [21]. In oSVZ, a distinct RG cell population termed as outer RG (oRG) is located peripherally and gives rise to a transit-amplifying population, which is an additional source of OPCs supplying the human cortex [19,21].

In the human forebrain, the first wave of OPCs originates from the medial ganglionic eminence (MGE) and the anterior entopeduncular area (AEP), while a second batch emerges postnatally from the lateral or caudal ganglionic eminences, establishing a sufficient amount of OPCs in the cerebral cortex [22]. OPCs of the human forebrain appear in the SVZ of the MGE at GW7.5, whilst at E12 in mice [19]. In the spinal cord, the majority of the nascent OPCs (about 80% of the total number) complete their formation at the motor neuron progenitor (pMN) domain of the ventral spinal cord, while the pool is enriched later at E15.5 by additional OPCs migrating from dorsal regions [23]. Lastly, the cerebellar OPCs are derived from the metencephalic ventral rhombomere 1 region, manifesting their presence at E16.5 and are reinforced additionally with a secondary population originating from the cerebellar VZ [10].
presence at E16.5 and are reinforced additionally with a secondary population originating from the cerebellar VZ [10].

Figure 1. Major cues of OPCs generation and differentiation during myelinogenesis in the prenatal period. In the neuroepithelium lining the neural tube, NSCs are under the influence of notochord-derived SHH, which drives the cells to become OPCs through OLIG2, SOX8/9/10 or follow neuronal fate (neuroblasts) via NGN1/2 and SOX1/2/3. BMP originated from the neural crest instructing NSCs to become astrocytes, controlled by HES1 as well. FOXJ1 is a crucial transcription factor for the ependymal trajectory. The positive and negative cues controlling OPCs differentiation are displayed in the upper right boxes. The hatched box depicts a representative area around sulcus limitans (between alar and basal plates). Dashed lines showcase naturally occurring processes, albeit not addressed in detail in the current review. ASCL1: Achaete-scute family bHLH transcription factor 1, BDNF: Brain-derived neurotrophic factor, BMP: Bone morphogenetic protein, CNTF: Ciliary neurotrophic factor, EGR1: Early growth response 1, EP: Ependymal cells, FOXJ1: Transcription factor forkhead box J1, GALC: Galactosylceramidase, GLI2: Glioma-associated oncogene family zinc finger 2, GPR17: G protein-coupled receptor 17, HES1: Hes family bHLH transcription factor 1, ID2: Inhibitor of DNA binding 2, ID4: Inhibitor of DNA binding 2, IGF-1: Insulin-like growth factor 1, JAG1: Jagged canonical Notch ligand 1, KLF6: Kruppel-like factor 6, MYRF: Myelin regulatory factor, NGN1: Neurogenin-1, NGN2: Neurogenin-2, NSC: Neural stem cells, NT-3: Neurotrophin 3, OL: Oligodendrocytes, OLIG1: Oligodendrocyte transcription factor 1, OLIG2: Oligodendrocyte transcription factor 2, OPC: Oligodendrocyte precursor cell, QKI: Quaking homolog, RG: Radial glia, SET domain bifurcated histone lysine methyltransferase 1, SETDB1: SHH: Sonic hedgehog signaling molecule, SIRT1: Sirtuin 1, SIRT2: Sirtuin 2, SOX: Sex-determining region Y-box transcription factor, SREBF2: Sterol regulatory element-binding transcription factor 2, T3: Triiodothyronine, TCF4: Transcription factor 4, ZFP191: Zinc finger protein 191.
2.2. Molecular Signals Driving Myelino-genesis

As has been articulated from the experimental evidence, the inauguration of myelino-genesis necessitates the formation of OPCs from multipotent NSCs, which ultimately give rise to mature myelinating OLs through a multistep process (Figure 1) [18,24]. A vital step herein lies in OPCs’ ability to migrate toward miscellaneous sites and proliferate, based predominately on environmental stimuli. These cells become post-mitotic, exiting the cell cycle to express a substantial amount of myelin-associated proteins and differentiate into mature pre-myelinating OLs [23]. Following the proper recognition, targeting and ensheathing specific nerve fibers is the subsequent critical milestone where each pioneer process creates lamellar extensions that stretch and elaborate circumferentially around the target axon [24]. As a new membrane is generated at the leading edge of the forming myelin sheath’s inner tongue, which starts to resemble a spiral cross-sectional shape, the sheath continues to spread along the axonal length. The secured stability and maintenance of a newly-formed myelin sheath is the concluding event. Specific developmental cues and molecular drivers regulate all the aforementioned cellular activities and are enlisted in full capacity in Tables A1–A3.

2.2.1. Formation of OPCs

OPCs being generated from the ventral VZ are under the influence of the morphogen molecule Sonic hedgehog (SHH) secreted from the notochord, while the dorsal counterparts are SHH-independent [25,26]. SHH signalling drives NSCs into a neuronal or OLs lineage fate superseding the effect of bone morphogenetic proteins (BMPs) which favour astroglial generation (Figure 1) [27,28]. Early secretion of SHH promotes motor neuron lineage formation, while interaction in later time periods promotes OLs differentiation [29]. Interestingly, the concentration of SHH can be controlled by sulfatase 1 expression in the ventral neuroepithelium prior to OPCs specification [30], whereas fibroblast growth factor (FGF) signalling is of paramount importance for further OLs differentiation, especially in the spinal cord [31,32].

Oligodendrocyte transcription factor 2 (OLIG2) is the primary regulator of OPCs generation [33,34], and its gene expression can be potentially repressed throughout the pre to postnatal period by paired box 6 (PAX6), Brahma-related gene-1 (BRG1), Iroquois homebox 3 (IRX3), histone deacetylase (HDAC) 1, HDAC2, Distal-less homebox (DLX) 1 and DLX 2 [35–41]. On the other hand, oligodendrocyte transcription factor 1 (OLIG1) is activated in later stages of OLs development [42]. Interestingly, the Hes family bHLH transcription factor (HES1) can drive RG to an astrocytic phenotype [43], while co-occurrence of OLIG2 with neurogenin-1 or neurogenin-2 supports motor neuron production [38,44,45]. Members of the sex-determining region Y-box transcription factor (SOX) family, such as SOX1, SOX2, and SOX3, can also direct OPCs towards a neuronal fate [33], in contrast to SOX8, SOX9, and SOX10, which favour the turnover of NSCs to OPCs in an autonomous manner [34–36]. Additionally, transcription factor forkhead box J1 (FOXJ1) supports the retention of RGs as ependymal cells throughout ventricles. Lastly, glioma-associated oncogene family zinc finger 2 (GLI2), myelin transcription factor 1 (MYT1), NK2 homeobox 6 (NKX2-6), and chromodomain-helicase-DNA-binding protein 8 (CHD8), among others (Table A1), are embryonic cues for OLs specification that vary within CNS regions indicating brain region specificity [37–40].

2.2.2. Migration

SHH presence is equally catalytic to OPCs migration [41]. Platelet-derived growth factor subunit A (PDGFA) and its cognate receptor, PDGF receptor alpha (PDGFRα), are essential positive drivers for OPCs migration [42]. In line with this, SOX5, SOX6, SOX9, and SOX10 stimulate the migration, ensuring PDGF responsiveness [43,44]. Chondroitin sulfate proteoglycan neuron-glia antigen 2 (NG2) and ephrin-B2/B3 molecules control OPCs polarity and contact abilities, promoting or intercepting migration, respectively [45,46]. Nestin, neural cell adhesion molecule (NCAM), and OLIG1 can also act as chemoattrac-
tants, determining cytoskeletal plasticity as well as OPCs motility [47–51]. Other migration chemoattractants are 2',3'-cyclic nucleotide 3' phosphodiesterase (CNPase), OLIG2, hepatocyte growth factor (HGF), thrombospondin 1, endothelin 1 (ET-1), oligodendrocyte specific protein (OSP), OSP–associated protein (OAP-1), N-cadherin (NCAD), merosin, fibronectin, and integrin subunit beta 1 (αvβ1 integrin) [52–60]. Spassky et al. suggested that netrin-1 is a candidate mediator for chemoattraction during migration [61]. However, other studies considered this molecule as a chemorepellent, antagonizing PDGF [62,63].

More growth factors and associated molecules, such as vascular endothelial growth factor A (VEGF-A) combined with VEGF receptor 2 (VEGFR2), can act as chemoattractant molecules for OPCs migration along with miscellaneous members of the transforming growth factor beta (TGF-β) family (e.g., BMP7 and BMP4), and Gαi-linked sphingosine-1-phosphate receptor (S1PR) 1 and S1PR3 [64–66]. In contrast to these specific sphingosine molecules, S1PR2 and S1PR5 negatively regulated migration [66]. Moreover, although C-X-C motif chemokine receptor (CXCR) 4, C-X-C motif chemokine ligand (CXCL) 12 and semaphorin 3F have chemoattractive effects on the OPCs migration, semaphorin 3A, CXCL1, and CXCR2 inhibit migration [61,67,68]. In addition, tenascin-c inhibited OPCs migration, whilst both claudin (CLDN) 1 and CLDN3 supported OPCs relocation, validated also in human specimens [59,69,70].

2.2.3. Proliferation

Specific driver molecules that participate in migration, such as PDGFA and PDGFRα, contribute additionally to the OPC proliferation [47,71]. Interestingly, in the spinal cord, the mitogenic effect of PDGF was enhanced by chemokine CXCL1 and CXCR2 [44,72], while CXCL12 had a proliferative effect on OPCs, mediated by its receptor CXCR4 [73]. More growth factors, such as FGF2, brain-derived neurotrophic factor (BDNF), and epidermal growth factor (EGF) are shown to play a vital role in OPCs proliferation [74–76].

Associate developmental pathways are also implicated in this step; PDGF-mediated proliferation depends largely on Wnt/β-catenin and PI3K/AKT/mTOR pathways [77,78]. Furthermore, jagged canonical Notch ligand 1 (JAG1) promotes OPCs proliferation and critically blocks the subsequent differentiation step [79]. Carrying on subcellular, CHD7 and CHD8 regulate gene expression in specific brain regions [80,81]. Another member of the SOX family, SOX9, supports the development of OLs in the cerebellum, regulating the timing of proliferation [82]. MYT1, NCAM, cyclin-dependent kinase inhibitor 1B (p27Kip1), oligodendrocyte myelin glycoprotein (OMgp), and tubulin polymerization promoting protein (TPPP) are negative regulator cues for OPCs proliferation [83–87]. Interestingly, overexpression of inhibitor of DNA binding (ID) 2 and ID4 enhances proliferation [88,89]. Similarly, expression of SHH, HGF, neurotrophin-4 (NT-4), nogg, superoxide dismutase 1 (SOD1), neurotrophin-3 (NT-3), achaete-scute family bHLH transcription factor 1 (ASCL1), PAX6, CLDN1, and CLDN3 promotes the proliferation process [41,54,70,90–95].

Integrin-mediated signalling and, more specifically, OSP, OAP-1, αvβ1 integrin, αvβ3 integrin, fibronectin and laminin are pivotal mediators in cytoskeletal remodelling of proliferating OPCs [56,96,97]. Gadea et al. revealed that ET-1 is a candidate molecule for enhancing cell migration without influencing proliferation [60]. Later, Adams and colleagues underscored that loss of ET-1 reduces OPCs proliferation in the developing SVZ via directly binding to endothelin type B receptor (ETBR) [98]. A reduced OPCs proliferation is observed in GS homeobox 1/2 (Gsx1/2) mutant embryos, whereas galectin-4 (GAL-4) treatment increased the proliferation [99,100]. At last, NRG1 and SOX2 induce cell division [101,102]; however, the latest data demonstrate that NRG1 acting via ErbB did not alter the proliferation state of OPCs [103].

2.2.4. Differentiation

OLIG1 and OLIG2 are heavily involved in the post-proliferating step of myelinosynthesis, defining the initiation of OPCs differentiation (Figure 1) [51,53,104], while BMPs seem to inhibit this process by downregulating myelin protein expression [105]. The effect can be
reversed by using a physiological antagonist of BMP4, such as noggin, which may restore differentiation [91,106,107]. OLIG2 appears to interact with a variety of factors, such as ASCL1, BRG1, transcription factor 4 (TCF4), and SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) to ensure proper OPCs differentiation [108–112]. G protein-coupled receptor 17 (GPR17) can act as a downregulator of OLIG1 that negatively controls the maturation and coordinates the generation of myelinating OLs from pre-myelinating OLs through ID proteins [113]. Although overexpression of ID2 and ID4 both regulate myelin gene expression by inhibiting OLs differentiation [89,114], they are not the major in vivo repressors of differentiation [115]. Moreover, decreased levels of OLG1 and myelin regulatory factor (MYRF) were observed under early growth response 1 (EGR1) and SOX11 overexpression, delineating the inhibitory action of the latest in OPCs differentiation [116,117]. Intriguingly, MYRF is a unique regulator participating in the late stages of OLs maturation and myelination, while the action of the other OLs’ lineage transcription factors is restricted on OPCs specification or initial differentiation of OLs [118].

SOX family proteins are also participating in the OLs differentiation. In particular, SOX2 and SOX3, through negative regulation of miR145, promote OLs maturation [119], while SOX5 and SOX6 increase PDGFRα expression, maintaining OLs in their immature state [44]. For the terminal differentiation of OLs, SOX8, SOX9, and SOX10 are required [82,120–122]. The state of myelogenesis-associated gene expression is uniformly affected by NKKX-2 and NKKX-6 [40,123,124]. Ji et al. suggested a mechanism regarding NKKX-2-mediated inhibition of OLs differentiation via regulation of sirtuin 2 (SIRT2), which generally is a positive cue for OLs maturation [125]. Similarly, sirtuin 1 (SIRT1) participates in the differentiation of OPCs during development [126] through cytoskeleton-related OLs proteins. The Kruppel-like factor 6 (KLF6) is another transcription factor promoting OPCs differentiation through glycoprotein 130 (GP130)-signal transducer and transcription activator 3 (STAT3) signalling [127]. Growth factor-wise, BDNF is a regulator of OLs differentiation operating via binding to tyrosine receptor kinase B (TrkB) and enhancing the MAPK pathway to upregulate gene expression during OLs maturation [75,77,128]. Evidently, NT-3 is important for the transition of immature OLs to myelin-forming cells by recruiting c-Fos protein-activating protein kinase C (PKC) and tyrosine kinase activities [129,130]. Insulin-like growth factor 1 (IGF-1) is another main factor in assisting the development of OPCs to mature OLs [131]. In accordance with that, GRB2 associated binding protein 1 (GAB1) absence decreased OLs differentiation, acting as a novel target of PDGF [132]. Incidentally, Canoll et al. suggested that NRG1 is a negative regulator of OPCs differentiation [101], while Brinkmann et al. later demonstrated that NRG1 is required for OPCs differentiation [103].

As far as metabolism is concerned, quaking homolog, KH domain RNA binding (QKI)-5 forms a complex with sterol regulatory element-binding transcription factor 2 (SREBF2) that regulates the transcription of genes responsible for cholesterol biosynthesis in OLs during differentiation [133]. Lack of transactive response DNA-binding protein 43 (TDP-43) results in lower SREBF2 and low-density lipoprotein receptor (LDLR) expression and cholesterol levels in vitro and in vivo, indicating the potential role of TDP-43 in cholesterol homeostasis in OLs, which is linked with the proper completion of OLs development [134]. In the same manner, ectonucleotide pyrophosphatase/phosphodiesterase 6 (ENPP6) participates in OLs maturation via a supplement of OLs with choline [135]. Most importantly, triiodothyronine (T3) is a key molecule for blocking OPCs proliferation and promoting their differentiation into mature OLs [136,137]. Thyroid hormone receptor alpha (TRα) is found both in OPCs and mature OLs, whilst thyroid hormone receptor isoform beta 1 (TRβ1) is located only in mature OLs [138]. The OPCs differentiation is mediated by the TRα, while TRβ1 is responsible for promoting myelogenesis in later stages [77]. Overexpression of HES5 decreases the levels of TRβ1 receptors, while ASCL1 increases them, demonstrating their role in regulating OLs differentiation timing [139]. The neurogenic locus notch homolog protein 1 (NOTCH1) is another receptor that also regulates the differentiation timing [140]. Interestingly, JAG1 is a receptor’s ligand responsible
for inhibiting OLs differentiation, while contactin 1 (CNTN1) is another ligand with the opposite function [79,141].

Other membrane molecules which repress OPCs differentiation are NCAM and leucine-rich repeat, and Ig-like domain-containing Nogo receptor interacting protein 1 (LINGO-1) [142,143]. OLs maturation is negatively affected by GAL-4 and galactosylceramidase (GALC), while prominin-1, GLI2, p21-activated kinase 1 (PAK1), myelin-associated glycoprotein (MAG), SOD1, ciliary neurotrophic factor (CNTF), and inward rectifying potassium channel 4.1 (Kir4.1) are crucial for proper differentiation [38,95,100,144–149]. On the other hand, proper completion of OLs differentiation requires zinc finger protein 191 (ZFP191) [150]. Microtubule-associated protein 2 (MAP2), microtubule-associated protein tau (MAPT), CNPase, and TPPP may be involved in OLs differentiation by organising the microtubule system, similar to fasciculation and elongation protein zeta 1 (FEZ1), which is responsible for developing OLs processes’ arbour [87,151–153]. Additionally, important molecules being involved in the completion of OLs development are OMgp, brain enriched myelin-associated protein 1 (BCAS1) and glutathione (GSH) [154–157]. Myelin proteolipid protein (PLP) and myelin basic protein (MBP) are the main myelin structural proteins, but it is suggested that they play an additional role in OLs differentiation [158,159]. CLDN1 and CLDN3 control MBP, OLIG2, PLP, and SOX10 expression: these molecules are essential for OLs differentiation, indicating that claudins are needed [70]. Finally, connexin 47 (CX47) and adenosine triphosphate binding cassette subfamily D member 1 (ABCD1) may support OLs during their differentiation, aiding in gap junction coupling and reducing oxidative stress, respectively [160–164].

2.2.5. Ensheathment

Multiple positive cues are important for the inauguration of ensheathment (Figure 2). Amongst the prime ones with a positive effect on axon-glial junction maintenance is NCAD, which regulates the interaction between OLs processes and axons [165]. The L1 cell adhesion molecule (L1-CAM) and laminin expressed in axons bind to contactin and integrin located in OLs [166]. Upon the formation of the first loops/wraps, neurofascin 155 (NF155), located in paranodal loops, forms a well-defined complex with contactin-associated protein (CASPR) and CNTN1, transmembrane proteins which are expressed in axons [167–169]. The activation of this complex has a pivotal role in myelin targeting, sheath growth, organisation of paranodal loops and, therefore, supporting the axoglial junction [170,171]. However, CASPR does not participate in myelin targeting [170]. In juxtaparanodes, the axoglial junction is strengthened when transient axonal glycoprotein-1 (TAG-1), a crucial molecule for maintaining enrichment of Kv1.1/Kv1.2 channels [172], interacts with CASPR2. Regarding internodal axoglial adhesion, glial cell adhesion molecule (CADM) 4 binds to axonal CADM2 and CADM3, facilitating myelin targeting, axon wrapping, and myelin sheath growth [173]. Similarly, CADM1b strongly binds to axonal CADM2, positively regulating ensheathment and strengthening the junction [174]. In the same region of the myelin sheath, MAG binds to ganglioside in axons, especially ganglioside GD1a and GT1b, and enforces the junction’s stability [175,176].

Based on several studies, ephrins (A, B) and cognate receptors (A, B) have dual roles that rely on location and expression. While ephrin receptor (Eph) A4 in OLs is activated by axonal ephrin-A1 ligand, which inhibits the stability of axoglial junctions needed for ensheathment, EphA4, expressed in the axon surface, interacts with ephrin-B, promoting myelin sheet formation [177,178]. In addition, EphB1 of axons is activated through ephrin-B in OLs, which in turn stimulates myelogenesis [178]. The axonal ephrinB2 via binding with EphB OLs receptor influences integrin activation, reducing myelin sheet formation [178]. The list of negative cues includes LINGO-1, which is located in both axons and OLs, and self-interacts in trans to control the number of targeted axons inhibiting myelogenesis [143,179]. The NCAM is a cell adhesion molecule negatively regulating myelogenesis. The downregulation of this protein is essential for promoting myelin formation during development, as myelogenesis occurs only on NCAM negative axons [180].
A somatodendritic protein, junctional adhesion molecule 2 (JAM2) inhibits oligodendroglial interaction, suppressing myelinogenesis [181]. Apart from the somatodendritic molecules, GAL-4 is expressed only to unmyelinated segments of neurons in hippocampal and cortical regions; this protein is demonstrated as the first identified inhibitor of myelinogenesis in axons [182]. Of particular interest is the possible role of OLIG1 in axonal recognition during myelinogenesis (Table A2) [183].

Figure 2. Axoglial driving cues for the initiation of ensheathment during myelinogenesis. A process of oligodendrocyte (blue) approaches the axon (brown) based on their surfaces’ attractive and repulsive signals. The red-colored shapes represent negative surface molecules; the green ones stand for positive and the yellow for bidirectional signals. For illustrational purposes, the paranode, juxtaparanode, and internode regions are simplified. CADM1b: Cell adhesion molecule 1b, CADM2: Cell adhesion molecule 2, CADM3: Cell adhesion molecule 3, CADM4: Cell adhesion molecule 4, CASPR: Contactin-associated protein, CASPR2: Contactin-associated protein-like 2, CNTN1: Contactin 1, EphA4: Ephrin receptor A4, EphB: Ephrin receptor B, EphB1: Ephrin receptor B1, GAL-4: Galectin-4, GD1a: Ganglioside GD1a, GT1b: Ganglioside GT1b, L1-CAM: L1 cell adhesion molecule, LINGO-1: Leucine-rich repeat and Ig-like domain-containing Nogo receptor interacting protein 1, MAG: Myelin-associated glycoprotein, NCAD: N-cadherin, NCAM: Neural cell adhesion molecule, NF155: Neurofascin 155, TAG-1: Transient axonal glycoprotein-1.

2.2.6. Myelin Sheath Growth and Preservation

The long-term membrane expansion and maintenance of the newly-formed myelin sheath is the final step in completing myelinogenesis and is utterly controlled by the major myelin proteins (Table A3). The most abundant myelin proteins are PLP (>50%) and MBP (~15%), having a significant role in the stabilization of the myelin structure [24,52,184]. The disruption of PLP gene expression presents impaired membrane compaction [185]. MAG, on the other side, is the third most abundant protein in CNS myelin (~5%), and does not seem to contribute to maintenance as much as it does to the previously described initial interaction between OLs and axons [147,186]. Interestingly, myelin oligodendrocyte glycoprotein (MOG) [187,188], CNPase [52,189], myelin-associated oligodendrocyte basic
protein (MOBP) [190], and OMgp [86,191,192], all minor CNS myelin proteins (<1%), need more investigation on how they influence the formation and maintenance of myelin sheaths in compact myelin.

OLs microtubule stability is mediated by MAP2 and MAPT [151], while CX32 and CX47 participate in maintenance [161]. Claudins, such as OSP, CLDN1, and CLDN3, play a pivotal role as well [70,185]. Transcription factors that participate in the lamellar extension process are SOX8, SOX10, NKX2-2, NKX6-2, and MYRF [35,122,193,194]. Transmembrane protein (TMEM) 98, which inhibits the self-cleavage of MYRF, ID4, and OLIG1, could also be involved in the process [114,195], whereas OLIG2 is expressed only until myelin membranes’ production is completed [183,196]. In addition, the ERK1/2 MAP kinase pathway is indispensable in maintaining myelinated axons via FGF–FGF receptor 1 and 2 (FGFR1 and FGFR2) [197,198]. Experiments in Hdad3-mutant optic nerves raised the possibility that HDAC3 is also necessary for myelin integrity [199].

Proper cholesterol biosynthesis is prioritized in myelogenesis, with QKI regulating this cholesterol production via SREBF2. Specifically, QKI-5 acts synergistically with peroxisome proliferator-activated receptor beta (PPARβ)-retinoid X receptor alpha (RXRα) activating transcription of the response in fatty acid metabolism genes. This operation of QKI-5 is significant for maintaining myelin homeostasis [133]. The ceramide galactosyl transferase (CGT) is a key enzyme for catalyzing GALC synthesis, while ceramide sulfotransferase (CST) is responsible for converting GALC to sulfatide [200,201]. Both CST and CGT mutant animals showed a regionally specific loss of myelin stability [200]. Thus, GALC and sulfatide have a pivotal role in the long-term maintenance of myelin, with the GALC being more crucial for myelin development than its assembly [200,201]. Additionally, peroxisomal metabolism also influences myelin survival [202]. For example, a peroxisomal transmembrane protein responsible for very long-chain fatty metabolism is encoded by the ABCD1 gene and is key in maintaining myelin stability [164,203]. Lastly, the age-dependent changes of TMEM10 might be linked with its action in maintaining CNS myelin [204].

2.3. Myelin Formation after Infancy

Although myelogenesis has been described in the nascent developmental years, myelination does naturally occur for the duration of a person’s life to promote learning and memory through brain circuit plasticity [205], or as remyelination after an injury [206]. The synaptic plasticity has been studied in depth; however, a newly discovered form of brain plasticity, namely myelin plasticity or myelin remodelling, is under intensive investigation [205]. Extrinsic factors can influence, either positively or negatively, this remodelling in the toddler, adolescent, and adult brain. For example, since myelin formation is sensitive to experience, sensory stimulation may upregulate myelination, while sensory or social deprivation can potentially downregulate axon ensheathment [205,207]. Myelin remodelling initiates when pre-existing OPCs recruit or directly differentiate into newly-formed mature OLs, whereas existing OLs have the ability to engage in plasticity [205]. The principal cues for this “adaptive” myelination should not be different from the ones we scrutinize in this review.

The regenerative process following injury also presents many similarities with specific steps of myelogenesis [208]. The neonatal OPCs are maintained in a resting, quiescent state through adulthood, and they are referred to as adult aOPCs, constituting ~6% of all cells in the CNS [206]. Interestingly, aOPCs have a transcriptome similar to mature OLs. After injury, the innate immune response activates aOPCs, transforming them into a neonatal-like transcriptome [209]. The activation of aOPCs is followed by their proliferation, migration, and final differentiation into mature OLs. Older literature describes these aOPCs as the primary remyelinating cells [210]. Nevertheless, newer research has suggested that neural progenitors in SVZ, Schwann cells, and surviving mature OLs are also implicated in the remyelinating process [211–213].
The myelination efficiency is age-dependent, as the impairment of aged OPCs to recruit and differentiate into mature OLs leads to decreased remodelling and remyelination [214]. The nutrient support of OLs is highly compromised in aging due to the presence of senescent astrocytes, leading to decreased cholesterol biosynthesis which in turn weighs in the impaired OLs membrane development [15,215,216]. This age-related energy depletion that decreases the myelination efficiency is further fed from the accumulation of DNA damage while rendering the neurons vulnerable to oxidative stress through free radicals [15,217]. Additionally, the ineffectiveness of microglia, which translates to aged phagocytes to clear out impaired myelin, is a potential aetiology for the downregulation of remyelination [218]. Taken all together, the detailed investigation of cues that drives de novo myelination could be a crucial point for revisiting them in demyelination and remyelination of the adult CNS, a concept that is discussed briefly in the following section.

3. Myelinogenesis in Disease and Beyond

Although aging is a natural process that leads to a decreased turnover of functional OLs and diminished myelin formation, the integrity of myelinogenesis can be highly compromised in pathological situations such as demyelination, characterized by extensive myelin loss [219]. This condition has to be distinguished from dysmyelination, which is a genetic-based anomaly affecting basic myelin proteins and leads to uneven/not properly compacted myelin sheaths [219]. Demyelinating diseases could be divided into many categories; according to their pathogenesis mechanism, which mostly implicate environmental factors, nutritional deficits, presence of myelinotoxic agents, or virus-mediated impairments. In quite frequent cases, immune system mediators are deregulated, leading to autoimmune inflammatory demyelination [219,220]. Among the three most prevalent inflammatory demyelinating diseases are multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM).

In this review, we summarized all the potential molecules responsible for the long-term maintenance of myelin along the axoglial junction (see Sections 2.2.5 and 2.2.6), serving simultaneously as key factors in demyelinating disease sequelae. Recent data revealed that impaired mitochondrial function and oxidative stress are also candidate pathophysiology mechanisms for demyelinating diseases [221]. Berghoff et al. demonstrated that disruption of cholesterol metabolism alters brain lipid metabolism in CNS and is associated with neurological diseases such as autoimmune inflammatory conditions, including MS [222]. Nonetheless, under such circumstances, an autoimmune attack generates myelin debris from damaged myelin [223]. These components impair the CNS remyelination by obstructing OPCs and OLs functionality while triggering additional deleterious immune responses, also known as epitope spreading [213,223,224]. The clearance of myelin debris is crucial for rearrangement since recent studies suggest that the failure of myelin clearance leads to inefficient remyelination [225,226].

Remyelination can be spontaneous or in an experimental setup, achieved by the providence of an exogenous source of neural precursor cells (NPCs) with myelinating potential [227,228]. In various transplantation paradigms, it is shown that these cells can either exert an in situ myelinating effect, as seen and applied successfully in spinal cord injury (SCI) cases [229,230], or by instructing and enhancing the capacity of endogenous cells to remyelinate, documented in experimental autoimmune encephalomyelitis (EAE) [208,231,232] (324). Proposed mechanisms of action also underlie immunomodulatory effects rather than direct cell replacement [233,234]. Nevertheless, the scarce population of surviving mature OLs after demyelination is shown to be less effective in comparison to newly created ones [213,235–237]. Towards this trajectory, which is a fully functional recruitment of aOPCs to form myelinating OLs [208,238] (324, 325), it is extremely important to comprehend the developmental molecular cues and factors governing the process of myelinogenesis (see Section 2.2.1, Section 2.2.2, Section 2.2.3, Section 2.2.4), since these same molecules can be candidate targets for therapeutic intervention in demyelinating diseases.
4. Conclusions

Through this comprehensive review, we attempt to list and categorize the genes and proteins that act as developmental morphogens to the CNS development and, more specifically, those that are activated in the process of oligodendrogenesis. The fully functional OLs, originating from unspecialized stem cells, are able to identify newly-formed axons which emanate and branch in regions that need fast conduction early in life, completing their task of myelinogenesis. Some of these cells persist in adult life in an intermediate, dormant phenotype scattered or organized around the primordial niches. An argument that was intended to bring into attention is how the powerful dynamics that shape myelination, which is naturally declining as we age, can be sustained, or even re-engaged after an injury or demyelinating disease. In the current era, transcriptomic profiling or metabolomic data can potentially give an answer as to which of the enlisted molecules, drivers, and regulators should be prioritized.

Author Contributions: I.D. and P.T., writing—original draft preparation and visualization; M.E.M., S.M. and D.M., conceptualization, review and editing; E.K., M.B., S.P. and N.G., review and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

OPCs Oligodendrocyte precursor cells
OLs Oligodendrocytes
CNS Central nervous system
NSCs Neural stem cells
aOPCs Adult oligodendrocyte precursor cells
E Embryonic day
GW Gestational week
VZ Ventricular zone
SVZ Subventricular zone
RG Radial glia
doSVZ Outer subventricular zone
MGE Medial ganglionic eminence
MS Multiple sclerosis
ABCD1 Adenosine triphosphate binding cassette subfamily D member 1
ASCL1 Achaete-scute family basic helix-loop-helix transcription factor 1
BDNF Brain-derived neurotrophic factor
BMP4 Bone morphogenetic protein 4
BMP7 Bone morphogenetic protein 7
CADM1b Cell adhesion molecule 1b
CADM2 Cell adhesion molecule 2
CADM3 Cell adhesion molecule 3
CADM4 Cell adhesion molecule 4
CASPR Contactin-associated protein
CASPR2 Contactin-associated protein-like 2
CGT Ceramide galactosyl transferase
CHD7 Chromdomain-helicase-DNA-binding protein 7
CHD8 Chromdomain-helicase-DNA-binding protein 8
CLDN1 Claudin 1
OSP Oligodendrocyte specific protein
CLDN3 Claudin 3
| Gene Symbol | Description |
|-------------|-------------|
| CNPase      | 2',3'-cyclic nucleotide 3' phosphodiesterase |
| CNTN1       | Contactin 1 |
| CST         | Ceramide sulfotransferase |
| CX32        | Connexin 32 |
| CX47        | Connexin 47 |
| CXCL1       | C-X-C motif chemokine ligand 1 |
| CXCL12      | C-X-C motif chemokine ligand 12 |
| CXCR2       | C-X-C motif chemokine receptor 2 |
| CXCR4       | C-X-C motif chemokine receptor 4 |
| DLX1        | Distal-less homeobox 1 |
| DLX2        | Distal-less homeobox 2 |
| EphA4       | Ephrin receptor A4 |
| EphB1       | Ephrin receptor B1 |
| EphB2       | Ephrin receptor B2 |
| ET-1        | Endothelin 1 |
| FGF2        | Fibroblast growth factor 2 |
| FGFR1       | Fibroblast growth factor receptor 1 |
| FGFR2       | Fibroblast growth factor receptor 2 |
| GAL-4       | Galectin-4 |
| GALS        | Galactosylceramidase |
| GLI2        | Glioma-associated oncogene family zinc finger 2 |
| HDAC1       | Histone deacetylase 1 |
| HDAC2       | Histone deacetylase 2 |
| HDAC3       | Histone deacetylase 3 |
| HES5        | Hairy and enhancer of split family basic helix-loop-helix transcription factor 5 |
| HGF         | Hepatocyte growth factor |
| ID2         | Inhibitor of DNA binding 2 |
| ID4         | Inhibitor of DNA binding 4 |
| JAG1        | Jagged canonical Notch ligand 1 |
| LINGO-1     | Leucine-rich repeat and Ig-like domain-containing Nogo receptor interacting protein 1 |
| MAG         | Myelin-associated glycoprotein |
| MAP2        | Microtubule-associated protein 2 |
| MAPT        | Microtubule-associated protein tau |
| MBP         | Myelin basic protein |
| MYRF        | Myelin regulatory factor |
| MYT1        | Myelin transcription factor 1 |
| NCAD        | N-cadherin |
| NCAM        | Neural cell adhesion molecule |
| NKK2-2      | NK2 homeobox 2 |
| NKK2-6      | NK2 homeobox 6 |
| NKK6-2      | NK6 homeobox 2 |
| NRG1        | Neuregulin 1 |
| NT-3        | Neurotrophin 3 |
| OAP-1       | Oligodendrocyte specific protein-associated protein |
| OLIG1       | Oligodendrocyte transcription factor 1 |
| OLIG2       | Oligodendrocyte transcription factor 2 |
| OMgp        | Oligodendrocyte myelin glycoprotein |
| PAX6        | Paired box 6 |
| PDGFA       | Platelet-derived growth factor subunit A |
| PDGFRα      | Platelet-derived growth factor receptor alpha |
| PLP         | Myelin proteolipid protein |
| QKI         | Quaking homolog, KH domain RNA binding |
| S1PR1       | Sphingosine-1-phosphate receptor 1 |
| S1PR2       | Sphingosine-1-phosphate receptor 2 |
| S1PR3       | Sphingosine-1-phosphate receptor 3 |
| S1PR5       | Sphingosine-1-phosphate receptor 5 |
| SHH         | Sonic hedgehog signaling molecule |
| BRG1        | Brahma-Related Gene-1 |
| SOD1        | Superoxide dismutase 1 |
SOX1  Sex-determining region Y-box transcription factor 1
SOX10 Sex-determining region Y-box transcription factor 10
SOX11 Sex-determining region Y-box transcription factor 11
SOX2  Sex-determining region Y-box transcription factor 2
SOX3  Sex-determining region Y-box transcription factor 3
SOX5  Sex-determining region Y-box transcription factor 5
SOX6  Sex-determining region Y-box transcription factor 6
SOX8  Sex-determining region Y-box transcription factor 8
SOX9  Sex-determining region Y-box transcription factor 9
SREBF2 Sterol regulatory element-binding transcription factor 2
TRα  Thyroid hormone receptor alpha
TRβ1  Thyroid hormone receptor isoform beta 1
TDP-43 Transactive response DNA-binding protein 43
TMEM10 Transmembrane Protein 10
TMEM98 Transmembrane protein 98
TPPP  Tubulin polymerization promoting protein
VEGF-A Vascular endothelial growth factor A
VEGFR2 Vascular endothelial growth factor receptor 2
αvβ1 integrin Integrin subunit beta 1
αvβ3 integrin Integrin subunit beta 3

Appendix A

The following appendix contains all the genes and relevant chromosomal loci from proteins involved in myelinogenesis in relation to their biological role. This data is supplemental to the main text based on the current knowledge and literature on cues driving oligodendrocyte development, ensheathment and myelin maintenance.

Table A1. Molecular drivers and morphogens in specification, migration, proliferation, and differentiation of OPCs.

| Gene *  | Chromosomal Locus * | Protein *                                      | Biological Role            | Reference |
|---------|---------------------|------------------------------------------------|---------------------------|-----------|
| ABCD1   | Xq28                | ATP binding cassette subfamily D member 1      | Differentiation            | [163,164] |
| ADGRG1  | 16q21               | Adhesion G protein-coupled receptor G1         | Proliferation              |          |
| ANOS1   | Xp22.31             | Anosmin                                       | Migration                  | [240]     |
| ASCL1   | 12q23.2             | Achaete-scute family bHLH transcription factor 1 | Specification; Proliferation; Differentiation | [93,108,139,241] |
| BCAS1   | 20q13.2             | Brain enriched myelin-associated protein 1     | Differentiation            | [156,157,242] |
| BDNF    | 11p14.1             | Brain-derived neurotrophic factor              | Proliferation; Differentiation; Specification; Proliferation; Differentiation | [75,128] |
| BMP2    | 20p12.3             | Bone morphogenetic protein 2                  | Specification; Differentiation; Migration; Differentiation | [27,105] |
| BMP4    | 14q22.2             | Bone morphogenetic protein 4                  | Differentiation            | [28,65,105,243] |
| BMP7    | 20q13.31            | Bone morphogenetic protein 7                  | Migration                  | [65]      |
| CDH2    | 18q12.1             | Cadherin 2                                     | Migration                  | [57]      |
| CDKN1B  | 12p13.1             | Cyclin-dependent kinase inhibitor 1B           | Proliferation              | [85]      |
| CHD7    | 8q12.2              | Chromodomain-helicase-DNA-binding protein 7    | Proliferation; Differentiation; Specification; Proliferation; Differentiation | [80,243] |
| CHD8    | 14q11.2             | Chromodomain-helicase-DNA-binding protein 8    | Differentiation            | [80,81]   |
| Gene   | Chromosomal Locus | Protein                  | Biological Role                        | Reference |
|--------|-------------------|--------------------------|----------------------------------------|-----------|
| CLDN1  | 3q28              | Claudin 1                | Migration; Proliferation; Differentiation | [70]      |
| CLDN3  | 7q11.23           | Claudin 3                | Migration; Proliferation               | [70]      |
| CLDN11 | 3q26.2            | Claudin 11               | Migration; Proliferation; Differentiation | [56]      |
| CNP    | 17q21.2           | 2′,3′-cyclic nucleotide 3′ phosphodiesterase | Migration; Proliferation            | [52,153] |
| CNTF   | 11q12.1           | Ciliary neurotrophic factor | Migration; Proliferation; Differentiation | [148,244]|
| CNTFR  | 9p13.3            | Ciliary neurotrophic factor receptor | Proliferation                          | [244]     |
| CNTN1  | 12q12             | Contactin 1              | Proliferation                          | [141]     |
| CREB3L2| 7q33              | CAMP responsive element binding protein 3 like 2 | Differentiation                        | [243]     |
| CSPG4  | 15q24.2           | Chondroitin sulfate proteoglycan 4 | Proliferation                          | [245]     |
| CXCL1  | 4q13.3            | C-X-C motif chemokine ligand 1 | Migration; Proliferation              | [67,72]   |
| CXCL12 | 10q11.21          | C-X-C motif chemokine ligand 12 | Migration; Proliferation              | [68,73]   |
| CXCR2  | 2q35              | C-X-C motif chemokine receptor 2 | Migration; Proliferation              | [67,72]   |
| CXCR4  | 2q22.1            | C-X-C motif chemokine receptor 4 | Migration; Proliferation              | [68,73]   |
| DLX1   | 2q31.1            | Distal-less homeobox 1   | Specification                          | [246]     |
| DLX2   | 2q31.1            | Distal-less homeobox 2   | Specification                          | [246]     |
| DUSP15 | 20q11.21          | Dual specificity phosphatase 15 | Differentiation                        | [247]     |
| EDN1   | 6p24.1            | Endothelin 1             | Migration; Proliferation              | [60,98]   |
| EDNRB  | 13q22.3           | Endothelin receptor type B | Proliferation                          | [98]      |
| EFNB2  | 13q33.3           | Ephrin B2                | Migration; Proliferation              | [46,248]  |
| EFNB3  | 17p13.1           | Ephrin B3                | Migration                              | [46]      |
| EGF    | 4q25              | Epidermal growth factor  | Proliferation                          | [76]      |
| EGR1   | 5q31.2            | Early growth response 1  | Differentiation                        | [116]     |
| ENPP6  | 4q35.1            | Ectonucleotide pyrophosphatase/phosphodiesterase 6 | Differentiation                        | [135]     |
| EPHB2  | 1p36.12           | Ephrin receptor B2       | Migration; Proliferation              | [46,248]  |
| FEZ1   | 11q24.2           | Fasciculation and elongation protein zeta | Differentiation                        | [152]     |
| FGF2   | 4q28.1            | Fibroblast growth factor 2 | Specification; Migration; Proliferation | [240,249]|
| FGFR1  | 8p11.23           | Fibroblast growth factor receptor 1 | Migration; Proliferation              | [240,249]|
| FGFR2  | 10q26.13          | Fibroblast growth factor receptor 2 | Specification                          | [31,249]  |
| FGFR3  | 4p16.3            | Fibroblast growth factor receptor 3 | Proliferation                          | [249]     |
| FLT1   | 13q12.3           | Fms related receptor tyrosine kinase 1 | Proliferation                          | [250]     |
| FN1    | 2q35              | Fibronectin 1            | Migration; Proliferation              | [59,96]   |
| GAB1   | 4q31.21           | GRB2-associated binding protein 1 | Differentiation                        | [132]     |
| GALT   | 14q31.3           | Galactosylceramidase     | Differentiation                        | [144]     |
| GDPD2  | Xq13.1            | Phosphodiesterase domain containing 2 | Proliferation                          | [244]     |
| GJC2   | 1q42.13           | Gap junction protein gamma 2 | Differentiation                        | [160–162,251]|
| GLI2   | 2q14.2            | GLI family zinc finger 2 | Specification; Differentiation         | [38]      |
| GPR17  | 2q14.3            | G protein-coupled receptor 17 | Differentiation                        | [113]     |
| GPR37  | 7q31.33           | G protein-coupled receptor 37 | Differentiation                        | [252]     |
| GSX1   | 13q12.2           | GS homeobox 1            | Proliferation                          | [99]      |
| GSX2   | 4q12              | GS homeobox 2            | Specification; Proliferation          | [99,253]  |
| HDAC1  | 1p35.2-p35.1      | Histone deacetylase 1    | Specification                          | [254,255]|
| HDAC2  | 6q21              | Histone deacetylase 2    | Specification                          | [254]     |
| HES1   | 3q29              | Hes family bHLH transcription factor 1 | Specification                        | [256]     |
| HES5   | 1p36.32           | Hes family bHLH transcription factor 5 | Differentiation                       | [139]     |
| Gene   | Chromosomal Locus | Protein                                               | Biological Role                  | Reference       |
|--------|-------------------|-------------------------------------------------------|----------------------------------|-----------------|
| HEY1   | 8q21.13           | Hes related family bHLH transcription factor with YRPW motif 1 | Differentiation                  | [257]           |
| HGF    | 7q21.11           | Hepatocyte growth factor                               | Migration; Proliferation         | [54]            |
| ID2    | 2p25.1            | Inhibitor of DNA binding 2                             | Proliferation; Differentiation   | [89,113,115]    |
| ID4    | 6p22.3            | Inhibitor of DNA binding 4, HLH protein                | Proliferation; Differentiation   | [88,113–115]    |
| IGF1   | 12q23.2           | Insulin-like growth factor 1                           | Differentiation                  | [74,131]        |
| IRX3   | 16q12.2           | Iroquois homeobox 3                                    | Specification; Mmigration;       | [37]            |
| ITGB1  | 10p11.22          | Integrin subunit beta 1                                | Proliferation; Differentiation   | [56,58,258]     |
| ITGB3  | 17q21.32          | Integrin subunit beta 3                                | Proliferation                    | [69,97]         |
| JAG1   | 20p12.2           | Jagged canonical Notch ligand 1                        | Proliferation; Differentiation   | [79]            |
| JUN    | 1p32.1            | Jun proto-oncogene, AP-1 transcription factor subunit  | Proliferation                    | [259,260]       |
| KCNJ10 | 1q23.2            | Potassium inwardly rectifying channel subfamily J member 10 | Differentiation                  | [149]           |
| KDR    | 4q12              | Kinase insert domain receptor                          | Migration; Proliferation         | [64,250]        |
| KLF6   | 10p15.2           | Kruppel-like factor 6                                  | Differentiation                  | [127]           |
| LAMA2  | 6q22.3            | Laminin subunit alpha 2                                | Migration; Proliferation         | [96,261]        |
| LAMA4  | 6q21              | Laminin subunit alpha 4                                | Migration; Proliferation         | [96,261]        |
| LAMA5  | 20q13.33          | Laminin subunit alpha 5                                | Migration; Proliferation         | [96,261]        |
| LGALS4 | 19q13.2           | Galectin-4                                            | Proliferation; Differentiation   | [100]           |
| LINGO1 | 15q24.3           | Leucine rich repeat and Ig domain containing 1         | Differentiation                  | [143]           |
| MAG    | 19q13.12          | Myelin-associated glycoprotein                         | Differentiation                  | [147]           |
| MAP2   | 2q34              | Microtubule-associated protein 2                       | Differentiation                  | [151]           |
| MAPT   | 17q21.31          | Microtubule-associated protein tau                     | Differentiation                  | [151]           |
| MBP    | 18q23             | Myelin basic protein                                   | Differentiation                  | [159]           |
| MOBP   | 3p22.1            | Myelin associated oligodendrocyte basic protein        | Differentiation                  | [190]           |
| MYOC   | 1q24.3            | Myocil                                                | Differentiation                  | [262]           |
| MYRF   | 11q12.2           | Myelin regulatory factor                               | Differentiation                  | [117]           |
| MYT1   | 20q13.33          | Myelin transcription factor 1                          | Proliferation                    | [39,83]         |
| NCAM1  | 11q23.2           | Neural cell adhesion molecule 1                        | Migration; Proliferation         | [47,48,84,142]  |
| NES    | 1q23.1            | Nestin                                                | Migration; Proliferation         | [49,263]        |
| NEUROG1| 5q31.1            | Neurogenin 1                                           | Specification                    | [37,264,265]    |
| NEUROG2| 4q25              | Neurogenin 2                                           | Specification                    | [37,264,265]    |
| NFIA   | 1p31.3            | Nuclear factor 1 A                                     | Specification                    | [37,266]        |
| NGF    | 1p13.2            | Nerve growth factor                                    | Proliferation; Differentiation   | [92,267]        |
| NKX2-2 | 20p11.22          | NK2 homeobox 2                                         | Specification; Proliferation;    | [37,108,123,124,|
|        |                   |                                                       | Differentiation;                | 268]            |
| NKX2-6 | 8p21.2            | NK2 homeobox 6                                         | Specification; Proliferation;    | [40]            |
| NKX6-1 | 4q21.23           | NK6 homeobox 1                                         | Specification                    | [26]            |
| NKX6-2 | 10q26.3           | NK6 homeobox 2                                         | Specification                    | [26]            |
| NOG    | 17q22             | Noggin                                                | Proliferation; Differentiation   | [91,106,107]    |
| NOTCH1 | 9q34.3            | Notch receptor 1                                       | Proliferation; Differentiation   | [79,140]        |
Table A1. Cont.

| Gene   | Chromosomal Locus | Protein                                | Biological Role                        | Reference        |
|--------|-------------------|----------------------------------------|----------------------------------------|------------------|
| NRG1   | 8p12              | Neuregulin 1                           | Migration; Proliferation; Differentiation | [101,103,269]    |
| NTF3   | 12p13.31          | Neurotrophin 3                         | Proliferation; Differentiation          | [92,129,130]     |
| NTF4   | 19q13.33          | Neurotrophin 4                         | Proliferation                          | [90]             |
| NTN1   | 17p13.1           | Nettin 1                               | Proliferation; Migration; Differentiation| [61–63]          |
| NTRK2  | 9q21.33           | Neurotrophic receptor tyrosine kinase 2 | Proliferation; Migration; Differentiation| [75,270]         |
| OLIG1  | 21q22.11          | Oligodendrocyte transcription factor 1  | Specification; Migration; Differentiation| [50,51,104,271]  |
| OLIG2  | 21q22.11          | Oligodendrocyte transcription factor 2  | Proliferation; Differentiation          | [51,53,271]      |
| OMG    | 17q11.2           | Oligodendrocyte myelin glycoprotein     | Proliferation; Differentiation          | [155]            |
| OPALIN | 10q24.1           | Oligodendrocytic myelin paranodal and inner loop protein | Differentiation | [272,273]      |
| PAK1   | 11q13.5-q14.1     | P21 (RAC1) activated kinase 1          | Differentiation                         | [146]            |
| PAX6   | 11p13             | Paired box 6                           | Specification; Proliferation            | [94,274,275]     |
| PDE5   | 4q26              | Phosphodiesterase 5A                   | Differentiation                         | [276]            |
| PDGFA  | 7p22.3            | Platelet-derived growth factor subunit A | Differentiation; Proliferation; Migration | [42,277]        |
| PDGFRA | 4q12              | Platelet-derived growth factor receptor alpha | Differentiation; Proliferation | [42,47,71,277]   |
| PLP1   | Xq22.2            | Proteolipid protein 1                  | Differentiation                         | [158]            |
| PRMT5  | 14q11.2           | Protein arginine methyltransferase 5    | Differentiation                         | [278]            |
| PROM1  | 4p15.32           | Prominin 1                             | Differentiation                         | [145]            |
| QKI    | 6q26              | QKI, KH domain containing RNA binding  | Differentiation                         | [133,279]        |
| RTN4   | 2p16.1            | Reticulon 4                            | Migration                               | [280]            |
| S1PR1  | 1p21.2            | Sphingosine-1-phosphate receptor 1      | Migration                               | [66]             |
| S1PR2  | 19p13.2           | Sphingosine-1-phosphate receptor 2      | Migration                               | [66]             |
| S1PR3  | 9q22.1            | Sphingosine-1-phosphate receptor 3      | Migration                               | [66]             |
| S1PR5  | 19p13.2           | Sphingosine-1-phosphate receptor 5      | Migration                               | [61]             |
| SEMA3A | 7q21.11           | Semaphorin 3A                          | Migration; Proliferation                | [61]             |
| SEMA3F | 3p21.31           | Semaphorin 3F                          | Differentiation                         | [112]            |
| SETDB1 | 1q21.3            | SET domain bifurcated histone lysine methyltransferase 1 | Differentiation | [27–30,32,41]  |
| SHH    | 7q36.3            | Sonic hedgehog signaling molecule       | Specification; Migration; Proliferation | [126]            |
| SIRT1  | 10q21.3           | Sirtuin 1                              | Differentiation                         | [125]            |
| SIRT2  | 19q13.2           | Sirtuin 2                              | Differentiation                         | [109,243]        |
| SMARCA4| 19p13.2           | SWI/SNF related, matrix associated, actin-dependent regulator of chromatin, subfamily a, member 4 | Differentiation; Proliferation | [95]             |
| SOD1   | 21q22.11          | Superoxide dismutase 1                 | Proliferation; Differentiation          | [33]             |
| SOX1   | 13q34             | SRY-box transcription factor 1         | Specification                           | [33]             |
| SOX2   | 3q26.33           | SRY-box transcription factor 2         | Differentiation; Proliferation          | [33,102,119]     |
| SOX3   | Xq27.1            | SRY-box transcription factor 3         | Differentiation                         | [33,119]         |
Table A1. Cont.

| Gene    | Chromosomal Locus * | Protein                                      | Biological Role                          | Reference |
|---------|---------------------|----------------------------------------------|------------------------------------------|-----------|
| SOX5    | 12p12.1             | SRY-box transcription factor 5              | Migration; Proliferation; Differentiation| [44]      |
| SOX6    | 11p15.2             | SRY-box transcription factor 6              | Migration; Proliferation; Differentiation| [44]      |
| SOX8    | 16p13.3             | SRY-box transcription factor 8              | Specification; Differentiation           | [34–36,120]|
| SOX9    | 17q24.3             | SRY-box transcription factor 9              | Migration; Proliferation; Differentiation| [36,44,82]|
| SOX10   | 22q13.1             | SRY-box transcription factor 10             | Migration; Differentiation               | [43,44,122,281]|
| SOX11   | 2p25.2              | SRY-box transcription factor 11             | Differentiation                          | [116]     |
| SP7     | 12q13.13            | Sp7 transcription factor                    | Differentiation                          | [243]     |
| SREBF2  | 22q13.2             | Sterol regulatory element-binding transcription factor 2 | Differentiation | [133]     |
| STAT3   | 17q21.2             | Signal transducer and activator of transcription 3 | Differentiation | [282]     |
| SULF1   | 8q13.2-q13.3        | Sulfatase 1                                 | Specification                            | [30]      |
| TARDBP  | 1p36.22             | TAR DNA binding protein                     | Differentiation                          | [134]     |
| TCF4    | 18q21.2             | Transcription factor 4                      | Differentiation                          | [110]     |
| TCF7L2  | 10q25.2-q25.3       | Transcription factor 7 like 2               | Differentiation                          | [111]     |
| THBS1   | 15q14               | Thrombospondin 1                            | Migration                                | [55]      |
| THRA    | 17q21.1             | Thyroid hormone receptor alpha              | Differentiation                          | [136–138]|
| TMEM98  | 17q11.2             | Transmembrane protein 98                    | Differentiation                          | [195]     |
| TNC     | 9q33.1              | Tenascin C                                  | Migration; Proliferation; Differentiation| [59,69]   |
| TPPP    | 5p15.33             | Tubulin polymerization promoting protein    | Proliferation; Differentiation           | [87]      |
| TSPAN3  | 15q24.3             | Tetraspanin 3                               | Migration; Proliferation                | [56]      |
| VEGFA   | 6p21.1              | Vascular endothelial growth factor A        | Migration; Proliferation                | [64,250]  |
| WDR1    | 4p16.1              | WD repeat domain 1                          | Differentiation                          | [279]     |
| YY1     | 14q32.2             | YY1 transcription factor                    | Differentiation                          | [283]     |
| ZBTB33  | Xq24                | Zinc finger and BTB domain containing       | Differentiation                          | [111]     |
| ZDHHC5  | 11q12.1             | Zinc finger DHHC-type palmitoyltransferase 5| Differentiation                          | [282]     |
| ZEB2    | 2q22.3              | Zinc finger E-box binding homeobox 2        | Differentiation                          | [284]     |
| ZNF24   | 18q12.2             | Zinc finger protein 24                      | Differentiation                          | [150]     |

* Data are retrieved from “The Human Protein Atlas” [285]. OPCs: Oligodendrocyte precursor cells.

Table A2. Regulators of axoglial interactions in myelin ensheathment.

| Gene    | Chromosomal Locus * | Protein                                      | Reference |
|---------|---------------------|----------------------------------------------|-----------|
| CADM1   | 11q23.3             | Cell adhesion molecule 1                     | [174]     |
| CADM2   | 3p12.1              | Cell adhesion molecule 2                     | [173,174]|
| CADM3   | 1q23.2              | Cell adhesion molecule 3                     | [173]     |
| CADM4   | 19q13.31            | Cell adhesion molecule 4                     | [173]     |
| CDH2    | 18q12.1             | Cadherin 2                                   | [165]     |
| CNTN1   | 12q12               | Contactin 1                                  | [167–169,171]|
| CNTN2   | 1q32.1              | Contactin 2                                  | [172]     |
| CNTNAP1 | 17q21.2             | Contactin-associated protein 1               | [167–170]|
| CNTNAP2 | 7q35–q36.1          | Contactin-associated protein 2               | [172]     |
### Table A2. Cont.

| Gene   | Chromosomal Locus | Protein                          | Reference   |
|--------|-------------------|----------------------------------|-------------|
| EFNA1  | 1q22              | Ephrin A1                        | [177]       |
| EFN2   | 13q33.3           | Ephrin B2                        | [178]       |
| EPHA4  | 2q36.1            | Ephrin receptor A4               | [177,178]  |
| EPHB1  | 3q22.2            | Ephrin receptor B1               | [178]       |
| JAM2   | 21q21.3           | Junctional adhesion molecule 2   | [181]       |
| L1CAM  | Xq28              | L1 cell adhesion molecule        | [166]       |
| LGALS4 | 19q13.2           | Galectin-4                       | [182]       |
| LINGO1 | 15q24.3           | Leucine rich repeat and Ig domain containing 1 | [143,179] |
| MAG    | 19q13.12          | Myelin-associated glycoprotein   | [176]       |
| NCAM1  | 11q23.2           | Neural cell adhesion molecule 1  | [180]       |
| NFASC  | 1q32.1            | Neurofascin                      |             |
| NRG1   | 8p12              | Neuregulin 1                     | [167–170]  |
| OLIG1  | 21q22.1           | Oligodendrocyte transcription factor 1 | [183]       |
| ST3GAL2| 16q22.1           | ST3 beta-galactoside alpha-2,3-sialyltransferase 2 | [175,176] |
| ST3GAL3| 1p34.1            | ST3 beta-galactoside alpha-2,3-sialyltransferase 3 | [175,176] |
| WASL   | 7q31.32           | WASP-like actin nucleation factor | [288,289]  |

* Data are retrieved from “The Human Protein Atlas” [285].

### Table A3. Molecules implicated in myelin growth and preservation.

| Gene   | Chromosomal Locus | Protein                                | Reference   |
|--------|-------------------|----------------------------------------|-------------|
| ABCD1  | Xq28              | ATP binding cassette subfamily D member 1 | [164,203]  |
| AGPS   | 2q31.2            | Alkylglycerone phosphate synthase       | [24,290]    |
| CA2    | 8q21.2            | Carboxy anhydrase 2                    | [291]       |
| CLDN1  | 3q28              | Claudin 1                              | [70]        |
| CLDN3  | 7q11.23           | Claudin 3                              | [70]        |
| CLDN11 | 3q26.2            | Claudin 11                             | [185]       |
| CNP    | 17q21.2           | 2′,3′-cyclic nucleotide 3′ phosphodiesterase | [52,189]    |
| DUSP15 | 2q11.21           | Dual specificity phosphatase 15        | [247]       |
| FGF1   | 5q31.3            | Fibroblast growth factor 1             | [198]       |
| FGF2   | 4q28.1            | Fibroblast growth factor 2             | [198]       |
| FGR1   | 8p11.23           | Fibroblast growth factor receptor 1    | [197,198]  |
| FGR2   | 10q26.13          | Fibroblast growth factor receptor 2    | [197,198]  |
| GAL3ST1| 22q12.2           | Galactose-3-O-sulfotransferase 1       | [200]       |
| GALK   | 14q31.3           | Galactosylceramidase                   | [200,201]  |
| GFAP   | 17q21.31          | Gial fibrillary acidic protein          | [292]       |
| GJB1   | Xq13.1            | Gap junction protein beta 1            | [161]       |
| GJC2   | 1q42.13           | Gap junction protein gamma 2           | [161]       |
| GNPAT  | 1p42.2            | Glycerophosphate O-acyltransferase     | [290]       |
| HDAC3  | 5q31.3            | Histone deacetylase 3                 | [199]       |
| ID4    | 6p22.3            | Inhibitor of DNA binding 4, HLH protein | [114]       |
| MAG    | 19q13.12          | Myelin-associated glycoprotein         | [147,186]  |
| MAL    | 2q11.1            | Mal, T cell differentiation protein    | [293]       |
| MAP2   | 2q34              | Microtubule-associated protein 2       | [151]       |
| MAPT   | 17q11.31          | Microtubule-associated protein tau     | [151]       |
| MBP    | 18q23             | Myelin basic protein                   | [52]        |
| MBP    | 18q23             | Myelin-associated oligodendrocyte basic protein | [190]       |
| MOG    | 6p22.1            | Myelin oligodendrocyte glycoprotein    | [187,188]  |
| NBRF   | 11q12.2           | Myelin regulatory factor               | [193]       |
| NCAM1  | 11q23.2           | Neural cell adhesion molecule 1        | [294]       |
| NKX2-2 | 20p11.22          | NK2 homeobox 2                        | [194]       |
| NKX2-6 | 8p21.2            | NK2 homeobox 6                        | [194]       |
| NPC1   | 18q11.2           | NPC intracellular cholesterol transporter 1 | [295]       |
Table A3. Cont.

| Gene * | Chromosomal Locus * | Protein * | Reference |
|--------|---------------------|-----------|-----------|
| OLIG1  | 21q22.11            | Oligodendrocyte transcription factor 1 | [183,196] |
| OLIG2  | 21q22.11            | Oligodendrocyte transcription factor 2 | [112,196] |
| OMG    | 17q11.2             | Oligodendrocyte myelin glycoprotein | [86,191,192] |
| OPALIN | 10q24.1             | Oligodendrocytic myelin paranodal and inner loop protein | [204] |
| PEX5   | 12p13.31            | Peroxisomal biogenesis factor 5 | [202] |
| PLP1   | Xq22.2              | Proteolipid protein 1 | [184,185] |
| PROM1  | 4p13.32             | Prominin 1 | [296] |
| QKI    | 6q26                | QKI, KH domain containing RNA binding | [133] |
| SETDB1 | 1q21.3              | SET domain bifurcated histone lysine methyltransferase 1 | [112] |
| SOX8   | 16p13.3             | SRY-box transcription factor 8 | [35] |
| SOX10  | 22q13.1             | SRY-box transcription factor 10 | [35,122] |
| SREBF2 | 22q13.2             | Sterol regulatory element-binding transcription factor 2 | [133] |
| TMEM98 | 17q11.2             | Transmembrane protein 98 | [195] |
| TPPP   | 5p15.33             | Tubulin polymerization promoting protein | [297] |
| UGT8   | 4q26                | UDP glycosyltransferase 8 | [200,201] |

* Data are retrieved from “The Human Protein Atlas” [285].

References
1. Allen, N.J.; Barres, B.A. Glia—More than Just Brain Glue. *Nature* 2009, 457, 675–677. [CrossRef] [PubMed]
2. Simons, M.; Nave, K.-A. Oligodendrocytes: Myelination and Axonal Support. *Cold Spring Harb. Perspect. Biol.* 2016, 8, a020479. [CrossRef] [PubMed]
3. Herculano-Houzel, S. The Glia/Neuron Ratio: How It Varies Uniformly across Brain Structures and Species and What That Means for Brain Physiology and Evolution: The Glia/Neuron Ratio. *Glia* 2014, 62, 1377–1391. [CrossRef] [PubMed]
4. Bercury, K.K.; Macklin, W.B. Dynamics and Mechanisms of CNS Myelination. *Dev. Cell* 2015, 32, 447–458. [CrossRef] [PubMed]
5. Nave, K.-A.; Werner, H.B. Myelination of the Nervous System: Mechanisms and Functions. *Annu. Rev. Cell Dev. Biol.* 2014, 30, 503–533. [CrossRef] [PubMed]
6. Boullere, A.I. The History of Myelin. *Exp. Neurol.* 2016, 283, 431–445. [CrossRef] [PubMed]
7. Edgar, J.M.; McGowan, E.; Chapple, K.J.; Möbius, W.; Lemgruber, L.; Insall, R.H.; Nave, K.; Boullerne, A. Rio-Hortega’s Drawings Revisited with Fluorescent Protein Defines a Cytoplasm-filled Channel System of CNS Myelin. *J. Anat.* 2021, 239, 1241–1255. [CrossRef] [PubMed]
8. Pérez-Cerdá, F.; Sánchez-Gómez, M.V.; Matute, C. Pío Del Río Hortega and the Discovery of the Oligodendrocytes. *Front. Neuroanat.* 2015, 9, 92. [CrossRef] [PubMed]
9. Martínez-Cerdeño, V.; Noctor, S.C. Neural Progenitor Cell Terminology. *Front. Neuroanat.* 2018, 12, 104. [CrossRef] [PubMed]
10. Van Tilborg, E.; de Theije, C.G.M.; van Hal, M.; Wagenaar, N.; de Vries, L.S.; Benders, M.J.; Rowitch, D.H.; Nijboer, C.H. Origin and Dynamics of Oligodendrocytes in the Developing Brain: Implications for Perinatal White Matter Injury. *Glia* 2018, 66, 221–238. [CrossRef] [PubMed]
11. Nishiyama, A.; Shimizu, T.; Sherafat, A.; Richardson, W.D. Life-Long Oligodendrocyte Development and Plasticity. *Semin. Cell Dev. Biol.* 2021, 116, 25–37. [CrossRef] [PubMed]
12. Scantlebury, N.; Cunningham, T.; Dockstader, C.; Laughlin, S.; Gaetz, W.; Rockel, C.; Dickson, J.; Mabbott, D. Relations between White Matter Maturation and Reaction Time in Childhood. *J. Int. Neuropsychol. Soc.* 2014, 20, 99–112. [CrossRef] [PubMed]
13. Mabbott, D.J.; Noseworthy, M.; Bouffet, E.; Laughlin, S.; Rockel, C. White Matter Growth as a Mechanism of Cognitive Development in Children. *Neurolmage* 2006, 33, 936–946. [CrossRef] [PubMed]
14. Young, K.M.; Psachoulia, K.; Tripathi, R.B.; Dunn, S.J.; Cossell, L.; Attwell, D.; Tohyama, K.; Richardson, W.D. Oligodendrocyte Dynamics in the Healthy Adult CNS: Evidence for Myelin Remodeling. *Neuron* 2013, 77, 873–885. [CrossRef] [PubMed]
15. Sams, E.C. Oligodendrocytes in the Aging Brain. *Neural Signal.* 2021, 5, NS20210008. [CrossRef] [PubMed]
16. Kinney, H.C.; Volpe, J.J. Chapter 8—Myelination Events. In *Volpe’s Neurology of the Newborn*, 6th ed.; Volpe, J.J., Inder, T.E., Darras, B.T., de Vries, L.S., du Plessis, A.J., Neil, J.J., Perlman, J.M., Eds.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 176–188, ISBN 978-0-323-42876-7.
17. Hughes, E.G.; Orthmann-Murphy, J.L.; Langseth, A.J.; Bergles, D.E. Myelin Remodeling through Experience-Dependent Oligodendrogenesis in the Adult Somatosensory Cortex. *Nat. Neurosci.* 2018, 21, 696–706. [CrossRef] [PubMed]
18. Grabel, L. Developmental Origin of Neural Stem Cells: The Glial Cell That Could. *Stem Cell Rev. Rep.* 2012, 8, 577–585. [CrossRef] [PubMed]
19. Fletcher, J.L.; Makowiecki, K.; Cullen, C.L.; Young, K.M. Oligodendrogenesis and Myelination Regulate Cortical Development, Plasticity and Circuit Function. *Semin. Cell Dev. Biol.* 2021, 118, 14–23. [CrossRef] [PubMed]
20. Bergles, D.E.; Richardson, W.D. Oligodendrocyte Development and Plasticity. *Cold Spring Harb. Perspect. Biol.* 2015, 8, a020453. [CrossRef]

21. Huang, W.; Bhaduri, A.; Velmeshov, D.; Wang, S.; Wang, L.; Rottkamp, C.A.; Alvarez-Buylla, A.; Rowitch, D.H.; Kriegstein, A.R. Origins and Proliferative States of Human Oligodendrocyte Precursor Cells. *Cell* 2020, 182, 594–608.e11. [CrossRef]

22. Kessaris, N.; Fogarty, M.; Iannarelli, P.; Grif, M.; Wegner, M.; Richardson, W.D. Competing Waves of Oligodendrocytes in the Forebrain and Postnatal Elimination of an Embryonic Lineage. *Nat. Neurosci.* 2006, 9, 173–179. [CrossRef] [PubMed]

23. Bradl, M.; Lassmann, H. Oligodendrocytes: Biology and Pathology. *Acta Neuropathol.* 2010, 119, 37–53. [CrossRef] [PubMed]

24. Baumann, N.; Plam-Dinh, D. Biology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System. *Physiol. Rev.* 2001, 81, 871–927. [CrossRef] [PubMed]

25. Tripathi, R.B.; Clarke, L.E.; Burzomato, V.; Kessaris, N.; Anderson, P.N.; Attwell, D.; Richardson, W.D. Dorsally and Ventrally Derived Oligodendrocytes Have Similar Electrical Properties but Myeline Prefered Tracts. *J. Neurosci.* 2011, 31, 6809–6819. [CrossRef]

26. Cai, J.; Qi, Y.; Hu, X.; Tan, M.; Liu, Z.; Zhang, J.; Li, Q.; Sander, M.; Qiu, M. Generation of Oligodendrocyte Precursor Cells from Mouse Dorsal Spinal Cord Independent of Nkx6 Regulation and Shh Signaling. *Neuron* 2005, 45, 41–53. [CrossRef] [PubMed]

27. Zhu, G.; Mehlter, M.F.; Zhao, J.; Yu Yung, S.; Kessler, J.A. Sonic Hedgehog and BMP2 Exert Opposing Actions on Proliferation and Differentiation of Embryonic Neural Progenitor Cells. *Dev. Biol.* 1999, 215, 118–129. [CrossRef] [PubMed]

28. Gomes, W.A.; Mehlter, M.F.; Kessler, J.A. Transgenic Overexpression of BMP4 Increases Astroglial and Decreases Oligodendroglial Lineage Commitment. *Dev. Biol.* 2003, 255, 164–177. [CrossRef]

29. Orentas, D.M.; Hayes, J.E.; Dyer, K.L.; Miller, R.H. Sonic Hedgehog Signaling Is Required during the Appearance of Spinal Cord Oligodendrocyte Precursors. *Dev. Camb. Eng.* 1999, 126, 2419–2429. [CrossRef]

30. Danesin, C.; Agius, E.; Escalas, N.; Ai, X.; Emerson, C.; Cochard, P.; Soula, C. Ventral Neural Progenitors Switch toward an Oligodendroglial Fate in Response to Increased Sonic Hedgehog (Shh) Activity: Involvement of Sulfitase 1 in Modulating Shh Signaling in the Ventral Spinal Cord. *J. Neurosci. Off. J. Soc. Neurosci.* 2006, 26, 5037–5048. [CrossRef]

31. Farreny, M.-A.; Agius, E.; Bel-Vialar, S.; Escalas, N.; Khouri-Farah, N.; Soukkaireh, C.; Danesin, C.; Pituello, F.; Coehard, P.; Soula, C. FGt Signaling Controls Shh-Dependent Oligodendroglial Fate Specification in the Ventral Spinal Cord. *Neural Develop.* 2018, 13, 3. [CrossRef] [PubMed]

32. Kearns, C.A.; Walker, M.; Ravanel, A.M.; Scott, K.; Arzbecker, M.R.; Appel, B. Zebrafish Spinal Cord Oligodendrocyte Formation Requires Boc Function. *Genetcs 2021*, 218, iyab082. [CrossRef] [PubMed]

33. Bylund, M.; Andersson, E.; Novitch, B.G.; Muhr, J. Vertebrate Neurogenesis Is Counteracted by Sox1–3 Activity. *Nat. Neurosci.* 2003, 6, 1162–1168. [CrossRef] [PubMed]

34. Stolt, C.C.; Schmitt, S.; Lommes, P.; Sock, E.; Wegner, M. Impact of Transcription Factor Sox8 on Oligodendrocyte Specification in the Mouse Embryonic Spinal Cord. *Dev. Biol.* 2005, 281, 309–317. [CrossRef] [PubMed]

35. Tumescu, T.; Arter, J.; Reiprich, S.; Tam, E.R.; Waisman, A.; Wegner, M. Sox8 and Sox10 Jointly Maintain Myelin Gene Expression in Oligodendrocytes. *Glia* 2018, 66, 279–294. [CrossRef]

36. Pozniak, C.D.; Langseth, A.J.; Dijkstra, G.J.P.; Choe, Y.; Werz, B.; Pleasure, S.J. Sox10 Directs Neural Stem Cells toward the Oligodendroglial Lineage by Decreasing Suppressor of Fused Expression. *Proc. Natl. Acad. Sci. USA* 2010, 107, 21795–21800. [CrossRef]

37. Wegner, M. Specification of Oligodendroglial Lineages. In *Patterning and Cell Type Specification in the Developing CNS and PNS*; Elsevier: Amsterdam, The Netherlands, 2020; pp. 847–866, ISBN 978-0-12-814405-3.

38. Qi, Y.; Tan, M.; Hui, C.C.; Qiu, M. Gli2 Is Required for Normal Shh Signaling and Oligodendrocyte Development in the Spinal Cord. *Mol. Cell. Neurosci.* 2003, 23, 440–450. [CrossRef]

39. Hudson, L.D.; Romm, E.; Berndt, J.A.; Nielsen, J.A. A Tool for Examining the Role of the Zinc Finger Myelin Transcription Factor 1 (Myt1) in Neural Development: Myt1 Knock-in Mice. *Transgenic Res.* 2011, 20, 951–961. [CrossRef] [PubMed]

40. Miron, V.E.; Kuhlmann, T.; Antel, J.P. Cells of the Oligodendroglial Lineage, Myelination, and Remyelination. *Biochim. Biophys. Acta BBA—Mol. Basis Dis.* 2011, 2012, 184–193. [CrossRef] [PubMed]

41. Merchan, P.; Bribián, A.; Sánchez-Camacho, C.; Lezama, M.; Bovolenta, P.; de Castro, F. Sonic Hedgehog Promotes the Migration and Proliferation of Optic Nerve Oligodendrocyte Precursors. *Mol. Cell. Neurosci.* 2007, 36, 355–368. [CrossRef] [PubMed]

42. Frost, E.E.; Zhou, Z.; Kransnesky, K.; Armstrong, R.C. Initiation of Oligodendrocyte Progenitor Cell Migration by a PDGF-A Activated Extracellular Regulated Kinase (ERK) Signaling Pathway. *Neurochem. Res.* 2009, 34, 169–181. [CrossRef]

43. Finzsch, M.; Stolt, C.C.; Lommes, P.; Wegner, M. Sox9 and Sox10 Influence Survival and Migration of Oligodendrocyte Precursors in the Spinal Cord by Regulating PDGF Receptor Aexression. *Development* 2008, 135, 637–646. [CrossRef] [PubMed]

44. Baroti, T.; Zimmermann, Y.; Schilling, A.; Liu, L.; Lommes, P.; Wegner, M.; Stolt, C.C. Transcription Factors Sox5 and Sox6 Exert Direct and Indirect Influences on Oligodendroglial Migration in Spinal Cord and Forebrain: SoxD Proteins in Oligodendrocyte Progenitors. *Glia* 2016, 64, 122–138. [CrossRef] [PubMed]

45. Biname, F.; Sakry, D.; Dimou, L.; Jolivet, V.; Trotter, J. NG2 Regulates Directional Migration of Oligodendrocyte Precursor Cells via Rho GTPases and Polarity Complex Proteins. *J. Neurosci.* 2013, 33, 10858–10874. [CrossRef] [PubMed]

46. Prestoz, L.; Chatzopoulou, E.; Lemkine, G.; Spassky, N.; Lebras, B.; Kagawa, T.; Ikenaka, K.; Zalc, B.; Thomas, J.-L. Control of Axonofinical Migration of Oligodendrocyte Precursor Cells by Eph–Ephrin Interaction. *Neuron Glia Biol.* 2004, 1, 73–83. [CrossRef]
47. Grinspan, J.B.; Franceschini, B. Platelet-Derived Growth Factor Is a Survival Factor for PSA-NCAM+ Oligodendrocyte Pre-
Progenitor Cells. J. Neurosci. Res. 1995, 41, 540–551. [CrossRef]
48. Decker, L.; Avellana-Adalid, V.; Nait-Oumesmar, B.; Durbec, P.; Baron-Van Evercooren, A. Oligodendrocyte Precursor Migration and Differentiation: Combined Effects of PSA Residues, Growth Factors, and Substrates. Mol. Cell. Neurosci. 2000, 16, 422–439. [CrossRef]
49. Gallo, V.; Armstrong, R. Developmental and Growth Factor-Induced Regulation of Nestin in Oligodendrocyte Lineage Cells. J. Neurosci. Res. 1995, 41, 394–406. [CrossRef]
50. Motizuki, M.; Isogaya, K.; Miyake, K.; Ikushima, H.; Kubota, T.; Miyazono, K.; Saitoh, M.; Miyazawa, K. Oligodendrocyte Transcription Factor 1 (Olig1) Is a Smad Cofactor Involved in Cell Motility Induced by Transforming Growth Factor-β. J. Biol. Chem. 2013, 288, 18911–18922. [CrossRef]
51. Zhou, Q.; Anderson, D.J. The BHLH Transcription Factors OLIG2 and OLIG1 Couple Neuronal and Glial Subtype Specification. Cell 2002, 109, 61–73. [CrossRef]
52. Yin, X.; Peterson, J.; Gravel, M.; Braun, P.E.; Trapp, B.D. CNP Overexpression Induces Aberrant Oligodendrocyte Membranes and Inhibits MBP Accumulation and Myelin Compaction. J. Neurosci. Res. 1997, 50, 238–247. [CrossRef]
53. Wegener, A.; Deboux, C.; Bachelin, C.; Frah, M.; Kerninon, C.; Sellhein, D.; Weider, M.; Wegner, M.; Nait-Oumesmar, B. Gain of Olig2 Function in Oligodendrocyte Progenitors Promotes Remyelination. Brain 2015, 138, 120–135. [CrossRef] [PubMed]
54. Yan, H.; Rivkees, S.A. Hepatocyte Growth Factor Stimulates the Proliferation and Migration of Oligodendrocyte Precursor Cells. J. Neurosci. Res. 2002, 69, 597–606. [CrossRef] [PubMed]
55. Scott-Drew, S.; ffrench-Constant, C. Expression and Function of Thrombospondin-1 in Myelinating Glial Cells of the Central Nervous System. J. Neurosci. Res. 1997, 50, 202–214. [CrossRef]
56. Tiwari-Woodruff, S.K.; Buznikov, A.G.; Vu, T.Q.; Micevych, P.; Chen, K.; Kornblum, H.I.; Bronstein, J.M. OSP/Claudin-11 Forms a Complex with a Novel Member of the Tetraspanin Super Family and Beta1 Integrin and Regulates Proliferation and Migration of Oligodendrocytes. J. Cell Biol. 2001, 153, 295–305. [CrossRef]
57. Payne, H.R.; Hemperly, J.J.; Lemmon, V. N-Cadherin Expression and Function in Cultured Oligodendrocytes. Dev. Brain Res. 1996, 97, 9–15. [CrossRef]
58. Milner, R.; Edwards, G.; Streuli, C.; ffrench-Constant, C. A Role in Migration for the Alpha V Beta 1 Integrin Expressed on Oligodendrocyte Precursors. J. Neurosci. Res. 1996, 44, 7240–7252. [CrossRef]
59. Froehner, C.H.; Kiernan, B.W.; Faissner, A.; ffrench-Constant, C. Regulation of Oligodendrocyte Precursor Migration by Extracellular Matrix: Evidence for Substrate-Specific Inhibition of Migration by Tenascin-C. Dev. Neurosci. 1996, 18, 266–273. [CrossRef]
60. Gadea, A.; Aguirre, A.; Haydar, T.F.; Gallo, V. Endothelin-1 Regulates Oligodendrocyte Development. J. Neurosci. 2009, 29, 10047–10062. [CrossRef]
61. Spassky, N.; de Castro, F.; Le Bras, B.; Heydon, K.; Quéraud-LeSaux, F.; Bloch-Gallego, E.; Chédotal, A.; Zalc, B.; Thomas, J.-L. Directional Guidance of Oligodendroglial Migration by Class 3 Semaphorins and Netrin-1. J. Neurosci. 2002, 22, 5992–6004. [CrossRef]
62. Jarjour, A.A.; Marritt, C.; Moore, S.W.; Thompson, K.M.; Yuh, S.-J.; Kennedy, T.E. Netrin-1 Is a Chemorepellent for Oligodendrocyte Precursor Cells in the Embryonic Spinal Cord. J. Neurosci. 2003, 23, 3735–3744. [CrossRef]
63. Tsai, H.-H.; Tessier-Lavigne, M.; Miller, R.H. Netrin-1 Mediates Spinal Cord Oligodendrocyte Precursor Dispersal. Development 2003, 130, 2095–2105. [CrossRef] [PubMed]
64. Zhang, H.; Vutsikis, L.; Pepper, M.S.; Kiss, J.Z. VEGF Is a Chemoattractant for FGF-2–Stimulated Neural Progenitors. J. Cell Biol. 2003, 163, 1375–1384. [CrossRef] [PubMed]
65. Choe, Y.; Huyhn, T.; Pleasure, S.J. Migration of Oligodendrocyte Precursor Cells Is Controlled by Transforming Growth Factor Family Proteins during Corticogenesis. J. Neurosci. 2014, 34, 14973–14983. [CrossRef] [PubMed]
66. Novgorodov, A.S.; El-Awani, M.; Bielawski, J.; Obeid, L.M.; Guzd, T.I. Activation of Sphingosine-1-phosphate Receptor S1P5 Inhibits Oligodendrocyte Progenitor Migration. EASEB J. 2007, 21, 1503–1514. [CrossRef]
67. Tsai, H.-H.; Frost, E.; To, V.; Robinson, S.; Ffrench-Constant, C.; Geertman, R.; Ransohoff, R.M.; Miller, R.H. The Chemokine Receptor CXCR2 Controls Positioning of Oligodendrocyte Precursors in Developing Spinal Cord by Arresting Their Migration. Cell 2002, 110, 373–383. [CrossRef]
68. Dziembowska, M.; Tham, T.N.; Lau, P.; Vitry, S.; Lazarini, F.; Dubois-Dalcq, M. A Role for CCR4 Signaling in Survival and Migration of Neural and Oligodendrocyte Precursors. Glia 2005, 50, 258–269. [CrossRef] [PubMed]
69. Garcia, R.; Ffrench-Constant, C. Knockout Mice Reveal a Contribution of the Extracellular Matrix Molecule Tenascin-C to Neural Precursor Proliferation and Migration. Dev. Camb. Engl. Brain Res. 2001, 128, 2485–2496. [CrossRef]
70. Chen, Y.; Zheng, Z.; Mei, A.; Huang, H.; Lin, F. Claudin-1 and Claudin-3 as Molecular Regulators of Myelination in Leukoaraiosis Patients. Clinics 2021, 76, e2167. [CrossRef]
71. Calver, A.R.; Hall, A.C.; Yu, W.-P.; Walsh, F.S.; Heath, J.K.; Betsholtz, C.; Richardson, W.D. Oligodendrocyte Population Dynamics and the Role of PDGF In Vivo. Neuron 1998, 20, 869–882. [CrossRef]
72. Robinson, S.; Tani, M.; Strier, R.M.; Ransohoff, R.M.; Miller, R.H. The Chemokine Growth-Regulated Oncogene-Alpha Promotes Spinal Cord Oligodendrocyte Precursor Proliferation. J. Neurosci. Off. J. Soc. Neurosci. 1998, 18, 10457–10463. [CrossRef] [PubMed]
Hashimoto, R.; Hori, K.; Owa, T.; Miyashita, S.; Dewa, K.; Masuyama, N.; Sakai, K.; Hayase, Y.; Seto, Y.; Inoue, Y.U.; et al. Origins

Veiga, S.; Ly, J.; Chan, P.H.; Bresnahan, J.C.; Beattie, M.S. SOD1 Overexpression Improves Features of the Oligodendrocyte Precursor Response in Vitro. *Neurosci. Lett.* 2011, 503, 10–14. [CrossRef] [PubMed]

Hu, J.; Deng, L.; Wang, X.; Xu, X.-M. Effects of Extracellular Matrix Molecules on the Growth Properties of Oligodendrocyte Precursor Cells in Vitro. *J. Neurosci. Res.* 2009, 87, 2854–2862. [CrossRef]

Blaschuk, K.L.; Frost, E.E.; ffrench-Constant, C. The Regulation of Proliferation and Differentiation in Oligodendrocyte Precursor Cells by AlphaV Integrins. *Dev. Camb. Engl.* J. Neurosci. Res. 2000, 69–78. [CrossRef]

Adams, K.L.; Riparini, G.; Banerjee, P.; Breur, M.; Bugiani, M.; Gallo, V. Endothelin-1 Signaling Maintains Glial Precursor Proliferation in the Postnatal Subventricular Zone. *Nat. Commun.* 2020, 11, 2138. [CrossRef]
99. Chapman, H.; Riesenber, A.; Ehrman, L.A.; Kohli, V.; Nardini, D.; Nakafuku, M.; Campbell, K.; Waclaw, R.R. Gsx Transcription Factors Control Neuronal versus Glial Specification in Ventricular Zone Progenitors of the Mouse Lateral Ganglionic Eminence. *Dev. Biol. 2018*, *442*, 115–126. [CrossRef]

100. Stanic, M.; Slijpecevic, D.; Nomed, A.; Vos, M.J.; de Jonge, J.C.; Sikkema, A.H.; Gabius, H.-J.; Hoekstra, D.; Baron, W. Galectin-4, a Novel Neuronal Regulator of Myelination. *Glia* 2012, *60*, 919–935. [CrossRef]

101. Canoll, F.D.; Musacchio, J.M.; Hardy, R.; Reynolds, R.; Marchionni, M.A.; Salzer, J.L. GGF/Neuregulin Is a Neuronal Signal That Promotes the Proliferation and Survival and Inhibits the Differentiation of Oligodendrocyte Progenitors. *Neuron* 1996, *17*, 229–243. [CrossRef]

102. Zhang, S.; Zhu, X.; Gui, X.; Croteau, C.; Song, L.; Xu, J.; Wang, A.; Bannewam, P.; Guo, F. Sox2 Is Essential for Oligodendroglial Proliferation and Differentiation during Postnatal Brain Myelination and CNS Remyelination. *J. Neurosci.* 2018, *38*, 1802–1820. [CrossRef]

103. Brinkmann, B.G.; Agarwal, A.; Sereda, M.W.; Garratt, A.N.; Müller, T.; Wende, H.; Stassart, R.M.; Nawaz, S.; Humml, C.; Velanac, V.; et al. Neuregulin-1/ErbB Signaling Serves Distinct Functions in Myelination of the Peripheral and Central Nervous System. *Neuron* 2008, *59*, 581–595. [CrossRef] [PubMed]

104. Dai, J.; Bercury, K.K.; Ahrendsen, J.T.; Macklin, W.B. Olig1 Function Is Required for Oligodendrocyte Differentiation in the Mouse Brain. *J. Neurosci. Off. J. Soc. Neurosci.* 2015, *35*, 4386–4402. [CrossRef] [PubMed]

105. See, J.; Zhang, X.; Erdyn, N.; Mun, S.-B.; Mamontov, P.; Golden, J.A.; Grinspan, J.B. Oligodendrocyte Maturation Is Inhibited by Bone Morphogenetic Protein. *Mol. Cell. Neurosci.* 2004, *26*, 481–492. [CrossRef] [PubMed]

106. Harnisch, K.; Teuber-Hansellmann, S.; Macha, N.; Mairinger, F.; Fritsche, L.; Souba, D.; Meinl, E.; Junker, A. Myelination in Multiple Sclerosis Lesions Is Associated with Regulation of Bone Morphogenetic Protein 4 and Its Antagonist Noggin. *Int. J. Mol. Sci.* 2019, *20*, 154. [CrossRef]

107. Izrael, M.; Zhang, P.; Kaufman, R.; Shinder, V.; Ella, R.; Amit, M.; Itskowitz-Eldor, J.; Chebath, J.; Revel, M. Human Oligodendrocytes Derived from Embryonic Stem Cells: Effect of Noggin on Phenotypic Differentiation in vitro and on Myelination in vivo. *Mol. Cell. Neurosci.* 2007, *34*, 310–323. [CrossRef]

108. Sugimori, M.; Nagao, M.; Parras, C.M.; Nakatani, H.; Lebel, M.; Guillemot, F.; Nakafuku, M. Ascl1 Is Required for Oligodendrocyte Development in the Spinal Cord. *Dev. Camb. Engl.* 2008, *135*, 1271–1281. [CrossRef]

109. Matsumoto, S.; Banine, F.; Feistel, K.; Foster, S.; Xing, R.; Struve, J.; Sherman, L.S. Brq1 Directly Regulates Olig2 Transcription and Is Required for Oligodendrocyte Progenitor Cell Specification. *Dev. Biol.* 2016, *413*, 173–187. [CrossRef] [PubMed]

110. Wedel, M.; Fröb, F.; Elesser, O.; Wittmann, M.-T.; Lie, D.C.; Reis, A.; Wegner, M. Transcription Factor Tcf4 Is the Preferred Heterodimerization Partner for Olig2 in Oligodendrocytes and Required for Differentiation. *Nucleic Acids Res.* 2020, *48*, 4839–4857. [CrossRef]

111. Zhao, C.; Deng, Y.; Liu, L.; Yu, K.; Zhang, L.; Wang, H.; He, X.; Wang, J.; Lu, C.; Wu, L.N.; et al. Dual Regulatory Switch through Interactions of Tcf7l2/Tcf4 with Stage-Specific Partners Propels Oligodendrogial Maturation. *Nat. Commun.* 2016, *7*, 10883. [CrossRef]

112. Zhang, K.; Chen, S.; Yang, Q.; Guo, S.; Chen, Q.; Liu, Z.; Li, L.; Jiang, M.; Li, H.; Hu, J.; et al. The Oligodendrocyte Transcription Factor 2 OLIG2 Regulates Transcriptional Repression during Myelogenesis in Rodents. *Nat. Commun.* 2022, *13*, 1423. [CrossRef]

113. Chen, Y.; Wu, H.; Wang, S.; Koiho, H.; Li, J.; Ye, F.; Hoang, J.; Escobar, S.S.; Gow, A.; Arnett, H.A.; et al. The Oligodendrocyte-Specific G Protein–Coupled Receptor GPR17 Is a Cell-Intrinsic Timer of Myelination. *Nat. Neurosci.* 2009, *12*, 1398–1406. [CrossRef] [PubMed]

114. Marin-Husstege, M.; He, Y.; Li, J.; Kondo, T.; Sablitzky, F.; Casaccia-Bonnefil, P. Multiple Roles of Id4 in Developmental Myelination: Predicted Outcomes and Unexpected Findings. *Glia* 2006, *54*, 285–296. [CrossRef] [PubMed]

115. Huang, H.; Wu, H.; He, W.; Zhou, F.; Yu, X.; Yi, M.; Du, J.; Xie, B.; Qiu, M. Id2 and Id4 Are Not the Major Negative Regulators of Oligodendroglial Differentiation during Early Central Nervous System Development. *Glia* 2022, *70*, 590–601. [CrossRef] [PubMed]

116. Swiss, V.A.; Nguyen, T.; Dugas, J.; Ibrahim, A.; Barres, B.; Androulakis, I.P.; Casaccia, P. Identification of a Gene Regulatory Network Necessary for the Initiation of Oligodendrocyte Differentiation. *PLoS ONE* 2011, *6*, e18088. [CrossRef] [PubMed]

117. Bujalaka, H.; Koenning, M.; Jackson, S.; Perreau, V.M.; Pope, B.; Hay, C.M.; Mitew, S.; Hill, A.F.; Lu, Q.R.; Wegner, M.; et al. MYRF Is a Membrane-Associated Transcription Factor That Autopoietically Cleaves to Directly Activate Myelin Genes. *PLoS Biol.* 2013, *11*, e1001625. [CrossRef]

118. Emery, B.; Agalliu, D.; Cahoy, J.D.; Watkins, T.A.; Dugas, J.C.; Mulinyawe, S.B.; Ibrahim, A.; Ligon, K.L.; Rowitch, D.H.; Barres, B.A. Myelin Gene Regulatory Factor Is a Critical Transcriptional Regulator for CNS Myelination. *Cell* 2009, *138*, 172–185. [CrossRef] [PubMed]

119. Hoffmann, S.A.; Hos, D.; Küspert, M.; Lang, R.A.; Lovell-Badge, R.; Wegner, M.; Reiprich, S. Stem Cell Factor Sox2 and Its Close Relative Sox3 Have Different Functions in Oligodendrocytes. *Development* 2014, *141*, 39–50. [CrossRef]

120. Stolt, C.C.; Lommes, P.; Friedrich, R.P.; Wegner, M. Transcription Factors Sox8 and Sox10 Perform Non-Equivalent Roles during Oligodendrocyte Development despite Functional Redundancy. *Development* 2004, *131*, 2349–2358. [CrossRef] [PubMed]

121. Stolt, C.C.; Rehberg, S.; Ader, M.; Lommes, P.; Riethmacher, D.; Schachner, M.; Bartsch, U.; Wegner, M. Terminal Differentiation of Myelin-Forming Oligodendrocytes Depends on the Transcription Factor Sox10. *Genes Dev.* 2002, *16*, 165–170. [CrossRef] [PubMed]

122. Takada, N.; Kucenas, S.; Appel, B. Sox10 Is Necessary for Oligodendrocyte Survival Following Axon Wrapping. *Glia* 2010, *58*, 996–1006. [CrossRef]
123. Zhang, C.; Huang, H.; Chen, Z.; Zhang, Z.; Lu, W.; Qiu, M. The Transcription Factor NKK2-2 Regulates Oligodendrocyte Differentiation through Domain-Specific Interactions with Transcriptional Corepressors. *J. Biol. Chem.* 2020, 295, 1879–1888. [CrossRef] [PubMed]

124. Qi, Y.; Cai, J.; Wu, Y.; Wu, R.; Lee, J.; Fu, H.; Rao, M.; Sussel, L.; Rubenstein, J.; Qiu, M. Control of Oligodendrocyte Differentiation by the Nkk2.2 Homeodomain Transcription Factor. *Dev. Camb. Engil.* 2001, 126, 2723–2733. [CrossRef] [PubMed]

125. Ji, S.; Doucette, J.R.; Nazarali, A.J. Sirt1 is a Novel in Vivo Downstream Target of Nkk2.2 and Enhances Oligodendroglial Cell Differentiation. *J. Mol. Cell Biol.* 2011, 3, 351–359. [CrossRef] [PubMed]

126. Hisahara, S.; Iwahara, N.; Matsushita, T.; Suzuki, S.; Matsumura, A.; Fujikura, M.; Yokokawa, K.; Saito, T.; Manabe, T.; Kawamata, J.; et al. SIRT1 Decelerates Morphological Processing of Oligodendroglial Cell Lines and Regulates the Expression of Cytoskeleton-Related Oligodendroglial Proteins. *Biochem. Biophys. Res. Commun.* 2021, 546, 7–14. [CrossRef]

127. Laitman, B.M.; Asp, L.; Mariani, J.N.; Zhang, J.; Liu, J.; Sawai, S.; Chapouly, C.; Horng, S.; Kramer, E.G.; Mitiku, N.; et al. The Transcriptional Interactions through Krüppel-like Factor-6 Is Required for CNS Myelination. *PLOS Biol.* 2016, 14, e1002467. [CrossRef]

128. Vondran, M.W.; Clinton-Luke, P.; Honeywell, J.Z.; Dreyfus, C.F. BDNF +/- Mice Exhibit Deficits in Oligodendroglial Lineage Cells of the Basal Forebrain. *Glia* 2010, 58, 848–856. [CrossRef] [PubMed]

129. Heinrich, M.; Gorath, M.; Richter-Landsberg, C. Neurotrophin-3 (NT-3) Modulates Early Differentiation of Oligodendrocytes. *J. Biol. Chem.* 2012, 287, 22184–22195. [CrossRef] [PubMed]

130. Vondran, M.W.; Clinton-Luke, P.; Honeywell, J.Z.; Dreyfus, C.F. BDNF +/- Mice Exhibit Deficits in Oligodendroglial Lineage Cells of the Basal Forebrain. *Glia* 2010, 58, 848–856. [CrossRef] [PubMed]

131. McMorris, F.A.; Dubois-Dalcq, M. Insulin-like Growth Factor I Promotes Cell Proliferation and Oligodendroglial Commitment in Rat Glial Progenitor Cells Developing in vitro. *J. Neurosci. Res.* 1988, 21, 199–209. [CrossRef]

132. Zhou, L.; Shao, C.-Y.; Xie, Y.-J.; Wang, N.; Xu, S.-M.; Luo, B.-Y.; Wu, Z.-Y.; Ye, Y.H.; Qiu, M.; Shen, Y. Gab1 Mediates PDGF Signaling and Is Essential to Oligodendroglial Differentiation and CNS Myelination. *eLife* 2020, 9, e52056. [CrossRef] [PubMed]

133. Zhou, L.; Shi, S.; He, C.; Zhang, Q.; Rasband, M.N.; Ren, J.; Dai, C.; Zorrilla-Veloz, R.I.; Shingu, T.; Yuan, L.; et al. Qki Regulates Myelogenesis through Srebp2-Dependent Cholesterol Biosynthesis. *eLife* 2021, 10, e60467. [CrossRef] [PubMed]

134. Ho, W.Y.; Chang, J.-C.; Lim, K.; Cazenave-Gassiot, A.; Nguyen, A.T.; Foo, J.C.; Muralidharan, S.; Viera-Ortiz, A.; Ong, S.J.M.; Hor, J.H.; et al. TDP-43 Mediates SREBF2-Regulated Gene Expression Required for Oligodendroglial Myelination. *J. Cell Biol.* 2021, 220, e201901213. [CrossRef] [PubMed]

135. Morita, J.; Kano, K.; Kato, K.; Takita, H.; Sakagami, H.; Yamamoto, Y.; Mihara, E.; Ueda, H.; Sato, T.; Tokuyama, H.; et al. Structure and Biological Function of ENPP6, a Choline-Specific Glycerophosphodiester-Phosphodiesterase. *Sci. Rep.* 2016, 6, 20995. [CrossRef] [PubMed]

136. Baas, D.; Bourbeau, D.; Sarlieve, L.L.; Ittel, M.E.; Dussault, J.H.; Puymirat, J. Oligodendrocyte Maturation and Progenitor Cell Proliferation Are Independently Regulated by Thyroid Hormone. *Glia* 1997, 19, 324–332. [CrossRef]

137. Barres, B.A.; Lazar, M.A.; Raff, M.C. A Novel Role for Thyroid Hormone, Glucocorticoids and Retinoic Acid in Timing Oligodendrocyte Development. *Dev. Camb. Engil.* 1994, 120, 1097–1108. [CrossRef] [PubMed]

138. Baas, D.; Fressinaud, C.; Ittel, M.E.; Reeper, A.; Dalençon, D.; Puymirat, J.; Sarlieve, L.L. Expression of Thyroid Hormone Receptor Isomers in Rat Oligodendroglial Cells. *Effect of 3,5,3'-Triiodo-L-Thyronine. Neurosci. Lett.* 1994, 176, 47–51. [CrossRef]

139. Kondo, T.; Raff, M. Basic Helix-Loop-Helix Proteins and the Timing of Oligodendrocyte Differentiation. *Dev. Camb. Engil.* 2000, 127, 2989–2998. [CrossRef] [PubMed]

140. Genoud, S.; Lappe-Sieckle, C.; Goebbels, S.; Radtke, F.; Aguet, M.; Scherer, S.S.; Suter, U.; Nave, K.-A.; Mantei, N. Notch1 Control of Oligodendrocyte Differentiation in the Spinal Cord. *J. Cell Biol.* 2002, 158, 709–718. [CrossRef]

141. Hu, Q.-D.; Ang, B.-T.; Karsak, M.; Hu, W.-P.; Cui, X.-Y.; Duka, T.; Takeda, Y.; Chia, W.; Sanak, N.; Ng, Y.-K.; et al. F3/Contactin Acts as a Functional Ligand for Notch during Oligodendroglial Maturation. *Cell 2003*, 115, 163–175. [CrossRef]

142. Emery, B. Regulation of Oligodendrocyte Differentiation and Myelination. *Science* 2010, 330, 779–782. [CrossRef]

143. Jepson, S.; Vought, B.; Gross, C.H.; Gan, L.; Austen, D.; Frantz, J.D.; Zwhahlen, J.; Lowe, D.; Markland, W.; Krauss, R. LINGO-1, a Transmembrane Signaling Protein, Inhibits Oligodendroglial Differentiation and Myelination through Intercellular Self-Interactions. *J. Biol. Chem.* 2012, 287, 22184–22195. [CrossRef] [PubMed]

144. Hirahara, Y.; Bansal, R.; Honke, K.; Ikenaka, K.; Wada, Y. Sulfatide Is A Negative Regulator of Oligodendroglial Differentiation: Development in Sulfatide-Null Mice. *Glia* 2004, 45, 269–277. [CrossRef] [PubMed]

145. Choi, M.-H.; Na, J.E.; Yoon, Y.R.; Rhyu, I.J.; Ko, Y.-G.; Baik, J.-H. Hypomyelination and Cognitive Impairment in Mice Lacking CD133 (Prominin-1). *Biochem. Biophys. Res. Commun.* 2018, 502, 291–298. [CrossRef]

146. Brown, T.L.; Hashimoto, H.; Finseth, L.T.; Wood, T.L.; Macklin, W.B. PAK1 Positively Regulates Oligodendroglial Morphology and Myelination. *J. Neurosci.* 2021, 41, 1864–1877. [CrossRef] [PubMed]

147. Quarles, R.H. Myelin-Associated Glycoprotein (MAG): Past, Present and Beyond. *J. Neurochem.* 2007, 100, 1431–1448. [CrossRef] [PubMed]

148. Stankoff, B.; Aigrot, M.-S.; Noël, F.; Wattilliaux, A.; Zale, B.; Lubetzki, C. Ciliary Neurotrophic Factor (CNTF) Enhances Myelin Formation: A Novel Role for CNTF and CNTF-Related Molecules. *J. Neurosci.* 2002, 22, 9221–9227. [CrossRef] [PubMed]

149. Kalsi, A.S.; Greenwood, K.; Wilkin, G.; Butt, A.M. Kir1.1 Expression by Astrocytes and Oligodendrocytes in CNS White Matter: A Developmental Study in the Rat Optic Nerve. *J. Anat.* 2004, 204, 475–485. [CrossRef]
150. Howng, S.Y.B.; Avila, R.L.; Emery, B.; Traka, M.; Lin, W.; Watkins, T.; Cook, S.; Bronson, R.; Davisson, M.; Barres, B.A.; et al. ZFP191 Is Required by Oligodendrocytes for CNS Myelination. *Genes Dev*. 2010, 24, 301–311. [CrossRef]

151. Müller, R.; Heinrich, M.; Heck, S.; Blöhm, D.; Richter-Landsberg, C. Expression of Microtubule-Associated Proteins MAP2 and Tau in Cultured Rat Brain Oligodendrocytes. *Cell Tissue Res.* 1997, 288, 239–249. [CrossRef]

152. Chen, X.; Xu, L.; Mei, R.; Liu, G.; Xu, C.; Wen, Z.; Zhao, X.; Wang, F.; Xiao, L.; Feng, Y. Novel Schizophrenia Risk Factor Pathways Regulate FEZ1 to Advance Oligodendroglia Development. *Transl. Psychiatry* 2017, 7, 1293. [CrossRef]

153. Lee, J.; Gravel, M.; Zhang, R.; Thibault, P.; Braun, P.E. Process Outgrowth in Oligodendrocytes Is Mediated by CNP, a Novel Microtubule Assembly Myelin Protein. *J. Cell Biol.* 2005, 170, 661–673. [CrossRef] [PubMed]

154. Monin, A.; Baumann, P.S.; Griffia, A.; Xin, L.; Mekle, R.; Fournier, M.; Butticaz, C.; Klaey, M.; Cabungcal, J.H.; Steullet, P.; et al. Glutathione Deficit Impairs Myelin Maturation: Relevance for White Matter Integrity in Schizophrenia Patients. *Mol. Psychiatry* 2015, 20, 827–838. [CrossRef] [PubMed]

155. Lee, X.; Hu, Y.; Zhang, Y.; Yang, Z.; Shao, Z.; Qi, M.; Pepinsky, B.; Miller, R.H.; Mi, S. Oligodendrocyte Differentiation and Myelination Defects in Omgp Null Mice. *Mol. Cell. Neurosci.* 2011, 46, 752–761. [CrossRef] [PubMed]

156. Kaji, S.; Maki, T.; Ueda, J.; Ishimoto, T.; Inoue, Y.; Yasuda, K.; Sawamura, M.; Hikawa, R.; Ayaki, T.; Yamakado, H.; et al. BCAS1-Positive Immature Oligodendrocytes Are Affected by the α-Synuclein-Induced Pathology of Multiple System Atrophy. *Acta Neuropathol. Commun.* 2020, 8, 120. [CrossRef] [PubMed]

157. Fard, M.K.; van der Meer, F.; Sánchez, P.; Cantuti-Castelvetri, L.; Mandad, S.; Jäkel, S.; Fornasiero, E.F.; Schmitt, S.; Ehrlich, M.; Starost, L.; et al. Early Expression Defines a Population of Early Myelinating Oligodendrocytes in Multiple Sclerosis Lesions. *Sci. Transl. Med.* 2017, 9, eaam7816. [CrossRef] [PubMed]

158. Ikenaka, K.; Kagawa, T.; Moser, H.; Poustka, A.M.; Mandel, J.L.; Aubourg, P. Putative X-Linked Adrenoleukodystrophy Gene Shares Unexpected Homology with ABC Transporters. *Acta Neuropathol. Commun.* 2020, 8, 239. [CrossRef] [PubMed]

159. Labasque, M.; Hivert, B.; Nogales-Gadea, G.; Querol, L.; Illa, I.; Faivre-Sarrailh, C. Specific Contactin N-Glycans Are Implicated in the CNS. *J. Neurosci.* 2003, 23, 5963–5973. [CrossRef]

160. Wasseff, S.K.; Scherer, S.S. Cx32 and Cx47 Mediate Oligodendrocyte:Astrocyte and Oligodendrocyte:Oligodendrocyte Gap Junction Coupling. *Neurobiol. Dis.* 2011, 42, 506–513. [CrossRef]

161. Mosser, J.; Douar, A.M.; Sarde, C.O.; Kioschis, P.; Feil, R.; Moser, H.; Poustka, A.M.; Mandel, J.L.; Aubourg, P. Putative X-Linked Adrenoleukodystrophy Gene Shares Unexpected Homology with ABC Transporters. *Nature* 1993, 361, 726–730. [CrossRef] [PubMed]

162. Wasseff, S.K.; Scherer, S.S. Cx32 and Cx47 Mediate Oligodendrocyte:Astrocyte and Oligodendrocyte Gap Junction Coupling. *Neurobiol. Dis.* 2011, 42, 506–513. [CrossRef]

163. Menichella, D.M.; Goodenough, D.A.; Sirkowski, E.; Scherer, S.S.; Paul, D.L. Connexins Are Critical for Normal Myelination in the CNS. *J. Neurosci.* 2003, 23, 5963–5973. [CrossRef]

164. Laursen, L.S.; Chan, C.W.; ffrench-Constant, C. An Integrin–Contactin Complex Regulates CNS Myelination by Differential Fyn Phosphorylation. *J. Neurosci.* 2009, 29, 9174–9185. [CrossRef]

165. Charles, P.; Tait, S.; Faivre-Sarrailh, C.; Barbin, G.; Gunn-Moore, F.; Denisenko-Nehrbass, N.; Guennoc, A.-M.; Girault, J.-A.; Starost, L.; et al. Association of TAG-1 with Caspr2 Is Essential for the Molecular Organization of Juxtaparanodal Regions of Myelinated Axons. *Mol. Cell. Neurosci.* 2003, 20, 827–838. [CrossRef] [PubMed]

166. Laursen, L.S.; Chan, C.W.; ffrench-Constant, C. An Integrin–Contactin Complex Regulates CNS Myelination by Differential Fyn Phosphorylation. *J. Neurosci.* 2009, 29, 9174–9185. [CrossRef] [PubMed]

167. Poole, R.J.; Brophy, P.J.; et al. Oligodendrocyte Neurofascin Independently Regulates Both Myelin Targeting and Sheath Growth Domain Organization in the Central Nervous System. *Dev. Cell* 2019, 51, 730–744.e6. [CrossRef]

168. Thaxton, C.; Pillai, A.M.; Pribisik, A.L.; Labasque, M.; Dupree, J.L.; Faivre-Sarrailh, C.; Bhat, M.A. In Vivo Deletion of Immunoglobulin Domains 5 and 6 in Neurofascin (Nfasc) Reveals Domain-Specific Requirements in Myelinated Axons. *J. Neurosci. Off. J. Soc. Neurosci.* 2010, 30, 4866–4876. [CrossRef] [PubMed]

169. Colakoglu, G.; Bergstrom-Tyberg, U.; Berglund, E.O.; Ranscht, B. Contactin-1 Regulates Myelination and Nodal/Paranodal Domain Organization in the Central Nervous System. *Proc. Natl. Acad. Sci. USA* 2014, 111, E394–E403. [CrossRef]

170. Traka, M.; Gouttebroze, L.; Denisenko, N.; Bessa, M.; Nifli, A.; Havaki, S.; Iwakura, Y.; Fukamauchi, F.; Watanabe, K.; Soliven, B.; et al. Association of TAG-1 with Caspr2 Is Essential for the Molecular Organization of Juxtaparanodal Regions of Myelinated Fibers. *J. Cell Biol.* 2003, 162, 1161–1172. [CrossRef]

171. Elazar, N.; Vainshtein, A.; Golan, N.; Vijayaragavan, B.; Schaeren-Wiemers, N.; Eshed-Eisenbach, Y.; Peles, E. Axoglial Adhesion by Cadm4 Regulates CNS Myelination. *Neuron* 2019, 101, 224–231.e5. [CrossRef] [PubMed]

172. Çolakoğlu, G.; Bergstrom-Tyberg, U.; Berglund, E.O.; Ranscht, B. Contactin-1 Regulates Myelination and Nodal/Paranodal Domain Organization in the Central Nervous System. *Proc. Natl. Acad. Sci. USA* 2014, 111, E394–E403. [CrossRef] [PubMed]
252. Yang, H.-J.; Vainshtein, A.; Maik-Rachline, G.; Peles, E. G Protein-Coupled Receptor 37 Is a Negative Regulator of Oligodendrocyte Differentiation and Myelination. Nat. Commun. 2016, 7, 10884. [CrossRef]

253. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

254. Ye, F.; Chen, Y.; Hoang, T.; Montgomery, R.L.; Zhao, X.; Bu, H.; Hu, T.; Taketo, M.M.; van Es, J.H.; Clevers, H.; et al. HDAC1 and HDAC2 Regulate Oligodendrocyte Differentiation by Disrupting the β-Catenin–TCF Interaction. Nat. Neurosci. 2009, 12, 829–838. [CrossRef]

255. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

256. Wu, Y.; Liu, Y.; Levine, E.M.; Rao, M.S. Hes1 but Not Hes5 Regulates an Astrocyte versus Oligodendrocyte Fate Choice in Glial Restricted Precursors. Dev. Dyn. Off. Publ. Am. Assoc. Anat. 2003, 226, 675–689. [CrossRef]

257. Havrda, M.C.; Paolaella, B.R.; Ran, C.; Jering, K.S.; Wray, C.M.; Sullivan, J.M.; Nailor, A.; Hithosi, Y.; Israel, M.A. Id2 Mediates Oligodendrocyte Precursor Cell Maturation Arrest and Is Tumorigenic in a PDGF-Rich Microenvironment. Cancer Res. 2014, 74, 1822–1832. [CrossRef]

258. Malek-Hedayat, S.; Rome, L.H. Expression of a Beta 1-Related Integrin by Oligodendroglia in Primary Culture: Evidence for a Functional Role in Myelinization. J. Cell Biol. 1994, 124, 1039–1046. [CrossRef]

259. Barres, B.A.; Raff, M.C. Control of Oligodendrocyte Number in the Developing Rat Optic Nerve. Neuron 1994, 12, 935–942. [CrossRef]

260. Miller, R.H. Regulation of Oligodendrocyte Development in the Vertebrate CNS. Prog. Neurobiol. 2002, 67, 451–467. [CrossRef]

261. Suzuki, N.; Hyodo, M.; Hayashi, C.; Mabuchi, Y.; Sekimoto, K.; Onchi, C.; Sekiguchi, K.; Akazawa, C.; Laminin A2, A4, and A5 Chains Positively Regulate Migration and Survival of Oligodendrocyte Precursor Cells. Sci. Rep. 2019, 9, 19882. [CrossRef]

262. Althaus, H.H.; Klöppner, S.; Schmidt-Schultz, T.; Schwartz, P. Nerve Growth Factor Induces Proliferation and Enhances Fiber Regeneration in Oligodendrocytes Isolated from Adult Pig Brain. Cancer Res. 2014, 74, 1822–1832. [CrossRef]

263. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

264. Wu, Y.; Liu, Y.; Levine, E.M.; Rao, M.S. Hes1 but Not Hes5 Regulates an Astrocyte versus Oligodendrocyte Fate Choice in Glial Restricted Precursors. Dev. Dyn. Off. Publ. Am. Assoc. Anat. 2003, 226, 675–689. [CrossRef]

265. Havrda, M.C.; Paolaella, B.R.; Ran, C.; Jering, K.S.; Wray, C.M.; Sullivan, J.M.; Nailor, A.; Hithosi, Y.; Israel, M.A. Id2 Mediates Oligodendrocyte Precursor Cell Maturation Arrest and Is Tumorigenic in a PDGF-Rich Microenvironment. Cancer Res. 2014, 74, 1822–1832. [CrossRef]

266. Deneen, B.; Ho, R.; Lukaszewicz, A.; Hochstim, C.J.; Gronostajski, R.M.; Anderson, D.J. The Transcription Factor NFIA Controls the Onset of Gliogenesis in the Developing Spinal Cord. Neuron 2001, 21, 757–771. [CrossRef]

267. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

268. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

269. Ortega, M.C.; Bribián, A.; Peregrín, S.; Gil, M.T.; Marín, O.; de Castro, F. Neuregulin-1/ErbB4 Signaling Controls the Migration of Pan-Neuronal and Subtype-Specific Properties of Motoneuron. Neuron 2001, 21, 757–771. [CrossRef]

270. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

271. Liu, Y.; Long, Z.; Yang, C. The Effects of the Olig Family on the Regulation of Spinal Cord Development and Regeneration. Neurochem. Res. 2021, 46, 2776–2782. [CrossRef]

272. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

273. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

274. Sun, T.; Pringle, N.P.; Hardy, A.P.; Richardson, W.D.; Smith, H.K. Pax6 Influences the Time and Site of Origin of Glial Precursors in the Ventral Neural Tube. Mol. Cell. Neurosci. 1998, 12, 228–239. [CrossRef] [PubMed]

275. Jang, E.S.; Goldman, J.E. Pax6 Expression Is Sufficient to Induce a Neurogenic Fate in Glial Progenitors of the Neonatal Subventricular Zone. PLoS ONE 2011, 6, e20894. [CrossRef] [PubMed]

276. Muñoz-Esquivel, J.; Götting, P.; Aguirre-Cruz, L.; Flores-Rivera, J.; Corona, T.; Reyes-Terán, G.; Küry, P.; Torres, K.J. Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells. ASN Neuro 2019, 11, 175909141983244. [CrossRef] [PubMed]

277. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

278. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]

279. Chapman, H.; Waclaw, R.R.; Pei, Z.; Nakafuku, M.; Campbell, K. The Homeobox Gene Gsx2 Controls the Timing of Oligodendroglial Fate Specification in Mouse Lateral Ganglionic Eminence Progenitors. Dev. Camb. Engl. 2013, 140, 2289–2298. [CrossRef]
278. Scaglione, A.; Patzig, J.; Liang, J.; Frawley, R.; Bok, J.; Mela, A.; Yattah, C.; Zhang, J.; Teo, S.X.; Zhou, T.; et al. PRMT5-Mediated Regulation of Developmental Myelination. *Nat. Commun.* **2018**, *9*, 2840. [CrossRef]

279. Doukhanine, E.; Gavino, C.; Haines, J.D.; Almazan, G.; Richard, S. The QKI-6 RNA Binding Protein Regulates Actin-Interacting Protein-1 MRNA Stability during Oligodendrocyte Differentiation. *Mol. Biol. Cell* **2010**, *21*, 3029–3040. [CrossRef]

280. Chong, S.Y.C.; Rosenberg, S.S.; Fancy, S.P.J.; Zhao, C.; Shen, Y.-A.A.; Hahn, A.T.; McGee, A.W.; Xu, X.; Zheng, B.; Zhang, L.L.; et al. Neurite Outgrowth Inhibitor Nogo-A Establishes Spatial Segregation and Extent of Oligodendrocyte Myelination. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 1299–1304. [CrossRef]

281. Hornig, J.; Fröb, F.; Vogl, M.R.; Hermans-Borgmeyer, I.; Tamm, E.R.; Wegner, M. The Transcription Factors Sox10 and Myrf Define an Essential Regulatory Network Module in Differentiating Oligodendrocytes. *PLoS Genet.* **2013**, *9*, e1003907. [CrossRef]

282. Ma, Y.; Liu, H.; Ou, Z.; Qi, C.; Xing, R.; Wang, S.; Han, Y.; Zhao, T.-J.; Chen, Y. DHHC5 Facilitates Oligodendrocyte Development by Palmitoylating and Activating STAT3. *Glia* **2022**, *70*, 379–392. [CrossRef]

283. He, Y.; Dupree, J.; Wang, J.; Sandoval, J.; Li, J.; Liu, H.; Shi, Y.; Nave, K.A.; Casaccia-Bonnefil, P. The Transcription Factor Yin Yang1 Is Essential for Oligodendrocyte Progenitor Differentiation. *Neuron* **2007**, *55*, 217–230. [CrossRef]

284. Weng, Q.; Chen, Y.; Wang, H.; Xu, X.; Yang, B.; He, Q.; Shou, W.; Chen, Y.; Higashi, Y.; van den Bergh, V.; et al. Dual-Mode Modulation of Smad Signaling by Smad-Interacting Protein Sip1 Is Required for Myelination in the Central Nervous System. *Neuron* **2012**, *73*, 713–728. [CrossRef] [PubMed]

285. The Human Protein Atlas. Available online: [https://www.proteinatlas.org/](https://www.proteinatlas.org/) (accessed on 22 June 2022).

286. Taveggia, C.; Thaker, P.; Petrylak, A.; Caporaso, G.L.; Toews, A.; Einheber, S.; Salzer, J.L. Type III Neuregulin-1 Variants of the Stem Cell Marker Prominin-1 (CD133) in Glial Cells. *Genet. Anal. Genet.* **2013**, *9*, 254–265. [CrossRef] [PubMed]

287. Bare, D.J.; Becker-Catania, S.G.; DeVries, G.H. Differential Localization of Neuregulin-1 Type III in the Central and Peripheral Nervous System. *Brain Res.* **2011**, *1369*, 10–20. [CrossRef] [PubMed]

288. Katanov, C.; Novak, N.; Vainshtein, A.; Golani, O.; Dupree, J.L.; Peles, E. N-Wasp Regulates Oligodendrocyte Myelination. *J. Neurosci.* **2020**, *40*, 6103–6111. [CrossRef] [PubMed]

289. Bacon, C.; Lakics, V.; Machesky, L.; Rumsby, M. N-WASP Regulates Extension of Filopodia and Processes by Oligodendrocyte Progenitors, Oligodendrocytes, and Schwann Cells—Implications for Axon Ensheathment at Myelination. *Glia* **2007**, *55*, 844–858. [CrossRef] [PubMed]

290. Malheiro, A.R.; Correia, B.; Ferreira da Silva, T.; Bessa-Neto, D.; Van Veldhoven, P.P.; Brites, P. Leukodystrophy Caused by Palmitoylating and Activating STAT3. *Glia* **2008**, *56*, 284–293. [CrossRef] [PubMed]

291. Kida, E.; Palminiello, S.; Golabek, A.A.; Walus, M.; Wierzba-Bobrowicz, T.; Rabe, A.; Albertini, G.; Wisniewski, K.E. Carbonic Anhydrase II in the Developing and Adult Human Brain. *J. Neuropathol. Exp. Neurol.* **2006**, *65*, 664–674. [CrossRef] [PubMed]

292. Liedtke, W.; Edelmann, W.; Bieri, P.L.; Chiu, F.-C.; Cowan, N.J.; Kucherlapati, R.; Raine, C.S. GFAP Is Necessary for the Integrity of CNS White Matter Architecture and Long-Term Maintenance of Myelination. *Neuron* **1996**, *17*, 607–615. [CrossRef]

293. Schaeren-Wiemers, N.; Bonnet, A.; Erb, M.; Erne, B.; Bartsch, U.; Kern, F.; Mantei, N.; Sherman, D.; Suter, U. The Raft-Associated Protein-1 MRNA Stability during Oligodendrocyte Differentiation. *Cell. Biol.* **2004**, *166*, 731–742. [CrossRef] [PubMed]

294. Fewou, S.N.; Ramakrishnan, H.; Büssow, H.; Gieselmann, V.; Eckhardt, M. Down-Regulation of Polysialic Acid Is Required for Efficient Myelin Formation. *J. Biol. Chem.* **2007**, *282*, 16700–16711. [CrossRef] [PubMed]

295. Yu, T.; Lieberman, A.P. Npc1 Acting in Neurons and Glia Is Essential for the Formation and Maintenance of CNS Myelin. *PLoS Genet.* **2013**, *9*, e1003462. [CrossRef] [PubMed]

296. Corbeil, D.; Joester, A.; Fargeas, C.A.; Jászai, J.; Garwood, J.; Hellwig, A.; Werner, H.B.; Huttner, W.B. Expression of Distinct Splice Variants of the Stem Cell Marker Prominin-1 (CD133) in Gial Cells. *Glia* **2009**, *57*, 860–874. [CrossRef] [PubMed]

297. Fu, M.-M.; McAlear, T.S.; Nguyen, H.; Oses-Prieto, J.A.; Valenzuela, A.; Shi, R.D.; Perrino, J.J.; Huang, T.-T.; Burlingame, A.L.; Bechstedt, S.; et al. The Golgi Outpost Protein TPPP Nucleates Microtubules and Is Critical for Myelination. *Cell* **2019**, *179*, 132–146.e14. [CrossRef] [PubMed]